In this third in a series of reviews on adjuvant drug-assisted bone healing, further approaches aiming at influencing the healing process are discussed. Local and systemic modulation of bone metabolism is pursued with use of a number of drugs with completely different indications, which are characterized by a pleiotropic spectrum of action. These include drugs used to treat lipid disorders (HMG-CoA reductase inhibitors), hypertension (ACE inhibitors), osteoporosis (bisphosphonates), cancer (proteasome inhibitors) and others. Potential applications to enhance bone healing are discussed.
BauerDC. HMG CoA reductase inhibitors and the skeleton: A comprehensive review. Osteoporos Int. 2003;14(4):273–82. doi: 10.1007/s00198-002-1323-x
2.
HughesA, RogersMJ, IdrisAI, CrockettJC. A comparison between the effects of hydrophobic and hydrophilic statins on osteoclast function in vitro and ovariectomy-induced bone loss in vivo. Calcif Tissue Int. 2007;81(5):403–13. doi: 10.1007/s00223-007-9078-1
3.
MaritzFJ, ConradieMM, HulleyPA, GopalR, HoughS. Effect of statins on bone mineral density and bone histomorphometry in rodents. Arterioscl Throm Vas. 2001;21(10):1636–41. doi: 10.1161/hq1001.097781
4.
TangQO, TranGT, GamieZ, GrahamS, TsialogiannisE, TsiridisE, et al. Statins: Under investigation for increasing bone mineral density and augmenting fracture healing. Expert Opin Investig Drugs. 2008;17(10):1435–63. doi: 10.1517/13543784.17.10.1435
5.
StojadinovicO, LebrunE, PastarI, KirsnerR, DavisSC, Tomic-CanicM. Statins as potential therapeutic agents for healing disorders. Expert Rev Dermatol. 2014;5(6):689–98. doi: 10.1586/edm.10.60
6.
GarrettI, GutierrezG, MundyG. Statins and Bone Formation. Curr Pharm Des. 2001;7(8):715–36. doi: 10.2174/1381612013397762
7.
MorseLR, CokerJ, BattaglinoRA. Statins and bone health: A mini review. Actual osteol. 2018;14(1):31–5.
8.
YueyiC, XiaoguangH, JingyingW, QuanshengS, JieT, XinF, et al. Calvarial defect healing by recruitment of autogenous osteogenic stem cells using locally applied simvastatin. Biomaterials. 2013;34(37):9373–80. doi: 10.1016/j.biomaterials.2013.08.060
9.
NyanM, MiyaharaT, NoritakeK, HaoJ, RodriguezR, KurodaS, et al. Molecular and tissue responses in the healing of rat calvarial defects after local application of simvastatin combined with alpha tricalcium phosphate. J Biomed Mater Res B Appl Biomater. 2010;93(1):65–73. doi: 10.1002/jbm.b.31559
10.
MoshiriA, SharifiAM, OryanA. Role of Simvastatin on fracture healing and osteoporosis: A systematic review on in vivo investigations. Clin Exp Pharmacol Physiol. 2016;43(7):659–84. doi: 10.1111/1440-1681.12577
11.
DimmelerS, AicherA, VasaM, Mildner-RihmC, AdlerK, TiemannM, et al. HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway. J Clin Invest. 2001;108(3):391–7. doi: 10.1172/JCI13152
Ghosh-ChoudhuryN, MandalCC, ChoudhuryGG. Statin-induced Ras activation integrates the phosphatidylinositol 3-kinase signal to Akt and MAPK for bone morphogenetic protein-2 expression in osteoblast differentiation. J Biol Chem. 2007;282(7):4983–93. doi: 10.1074/jbc.M606706200
ZhangM, BianY, TaoH, YangX, MuW. Simvastatin induces osteogenic differentiation of MSCs via Wnt/β-catenin pathway to promote fracture healing. Eur Rev Med Pharmacol Sci. 2018;22(9):2896–905. issn:1128-3602
16.
RotheR, SchulzeS, NeuberC, HauserS, RammeltS, PietzschJ. Adjuvant drug-assisted bone healing: Part I – Modulation of inflammation. Clin Hemorheol Microcirc. 2019;73(3):381–408. doi: 10.3233/CH-199102
17.
RotheR, SchulzeS, NeuberC, HauserS, RammeltS, PietzschJ. Adjuvant drug-assisted bone healing: Part II – Modulation of angiogenesis. Clin Hemorheol Microcirc2019;73(3):409–38. doi: 10.3233/CH-199103
18.
ShahSR, WerlangCA, KasperFK, MikosAG. Novel applications of statins for bone regeneration. Natl Sci Rev. 2015;2(1):85–99. doi: 10.1093/nsr/nwu028
19.
MaedaT, KawaneT, HoriuchiN. Statins augment vascular endothelial growth factor expression in osteoblastic cells via inhibition of protein prenylation. Endocrinology. 2003;144(2):681–92. doi: 10.1210/en.2002-220682
20.
IwataA, ShiraiR, IshiiH, KushimaH, OtaniS, HashinagaK, et al. Inhibitory effect of statins on inflammatory cytokine production from human bronchial epithelial cells. Clin Exp Immunol. 2012;168(2):234–40. doi: 10.1111/j.1365-2249.2012.04564.x
21.
ZambarakjiHJ, NakazawaT, ConnollyE, LaneAM, MallemadugulaS, KaplanM, et al. Dose-dependent effect of pitavastatin on VEGF and angiogenesis in a mouse model of choroidal neovascularization. Invest Ophthalmol Vis Sci. 2006;47(6):2623–31. doi: 10.1167/iovs.05-0855
22.
KureishiY, LuoZ, ShiojimaI, BialikA, FultonD, LeferDJ, et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med. 2000;6(9):1004–10. doi: 10.1038/79510
23.
WeisM. Statins Have Biphasic Effects on Angiogenesis. Circulation. 2002;105(6):739–45. doi: 10.1161/hc0602.103393
24.
ParkJ-B. The use of simvastatin in bone regeneration. Med Oral Patol Oral Cir Bucal. 2009;14(9):e485–e8.
25.
SegarCE, OgleME, BotchweyEA. Regulation of angiogenesis and bone regeneration with natural and synthetic small molecules. Curr Pharm Des. 2013;19(19):3403–19. doi: 10.2174/1381612811319190007
26.
UlkerP, OzenN, AbdullayevaG, KoksoyS, YarasN, BasraliF. Extracellular ATP activates eNOS and increases intracellular NO generation in Red Blood Cells. Clin Hemorheol Microcirc. 2018;68(1):89–101. doi: 10.3233/CH-170326
27.
KajiH, KanataniM, SugimotoT, ChiharaK. Statins modulate the levels of osteoprotegerin/receptor activator of NFkappaB ligand mRNA in mouse bone-cell cultures. Horm Metab Res. 2005;37(10):589–92. doi: 10.1055/s-2005-870538
28.
TsartsalisAN, DokosC, KaiafaGD, TsartsalisDN, KattamisA, HatzitoliosAI, et al. Statins, bone formation and osteoporosis: Hope or hype. Hormones (Athens). 2012;11(2):126–39. doi: 10.14310/horm.2002.1339
AhnKS, SethiG, ChaturvediMM, AggarwalBB. Simvastatin, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, suppresses osteoclastogenesis induced by receptor activator of nuclear factor-kappaB ligand through modulation of NF-kappaB pathway. Int J Cancer. 2008;123(8):1733–40. doi: 10.1002/ijc.23745
31.
MonjoM, RubertM, WohlfahrtJC, RønoldHJ, EllingsenJE, LyngstadaasSP. In vivo performance of absorbable collagen sponges with rosuvastatin in critical-size cortical bone defects. Acta Biomater. 2010;6(4):1405–12. doi: 10.1016/j.actbio.2009.09.027
32.
LinTK, LiouYS, LinCH, ChouP, JongGP. High-potency statins but not all statins decrease the risk of new-onset osteoporotic fractures: A nationwide population-based longitudinal cohort study. Clin Epidemiol. 2018;10:159–65. doi: 10.2147/CLEP.S145311
33.
OryanA, KamaliA, MoshiriA. Potential mechanisms and applications of statins on osteogenesis: Current modalities, conflicts and future directions. J Control Release. 2015;215:12–24. doi: 10.1016/j.jconrel.2015.07.022
34.
FukuiT, IiM, ShojiT, MatsumotoT, MifuneY, KawakamiY, et al. Therapeutic effect of local administration of low-dose simvastatin-conjugated gelatin hydrogel for fracture healing. J Bone Miner Res. 2012;27(5):1118–31. doi: 10.1002/jbmr.1558
35.
HamJ, EvansBA. An emerging role for adenosine and its receptors in bone homeostasis. Front Endocrinol (Lausanne). 2012;3:113. doi: 10.3389/fendo.2012.00113
36.
MedieroA, CronsteinBN. Adenosine and bone metabolism. Trends Endocrinol Metab. 2013;24(6):290–300. doi: 10.1016/j.tem.2013.02.001
37.
HaskoG, LindenJ, CronsteinB, PacherP. Adenosine receptors: Therapeutic aspects for inflammatory and immune diseases. Nat Rev Drug Discov. 2008;7(9):759–70. doi: 10.1038/nrd2638
38.
EvansBA, ElfordC, PexaA, FrancisK, HughesAC, DeussenA, et al. Human osteoblast precursors produce extracellular adenosine, which modulates their secretion of IL-6 and osteoprotegerin. J Bone Miner Res. 2006;21(2):228–36. doi: 10.1359/JBMR.051021
39.
DipRG. Adenosine receptor modulation: Potential implications in veterinary medicine. Vet J. 2009;179(1):38–49. doi: 10.1016/j.tvjl.2007.08.005
40.
KonT, ChoTJ, AizawaT, YamazakiM, NoohN, GravesD, et al. Expression of osteoprotegerin, receptor activator of NF-κB ligand (osteoprotegerin ligand) and related proinflammatory cytokines during fracture healing. J Bone Miner Res. 2001;16(6):1004–14. doi: 10.1359/jbmr.2001.16.6.1004
41.
VallsMD, CronsteinBN, MontesinosMC. Adenosine receptor agonists for promotion of dermal wound healing. Biochem Pharmacol. 2009;77(7):1117–24. doi: 10.1016/j.bc2008.11.002
42.
GaoZ-G, InoueA, JacobsonKA. On the G protein-coupling selectivity of the native A2B adenosine receptor. Biochem Pharmacol. 2017. doi: 10.1016/j.bc2017.12.003
43.
MüllerCE, JacobsonKA. Recent developments in adenosine receptor ligands and their potential as novel drugs. Biochim Biophys Acta. 2011;1808(5):1290–308. doi: 10.1016/j.bbamem.2010.12.017
44.
MontesinosMC, ShawJP, YeeH, ShamamianP, CronsteinBN. Adenosine A 2A receptor activation promotes wound neovascularization by stimulating angiogenesis and vasculogenesis. Am J Pathol. 2004;164(6):1887–92. doi: 10.1016/S0002-9440(10)63749-2
45.
LopezCD, BekiszJM, CorciuloC, MedieroA, CoelhoPG, WitekL, et al. Local delivery of adenosine receptor agonists to promote bone regeneration and defect healing. Adv Drug Deliv Rev. 2018. doi: 10.1016/j.addr.2018.06.010
46.
JacobsonKA, GaoZG. Adenosine receptors as therapeutic targets. Nat Rev Drug Discov. 2006;5(3):247–64. doi: 10.1038/nrd1983
CorciuloC, IrreraN, CronsteinBN. Adenosine Receptors Regulate Bone Remodeling and Cartilage Physiology. The Adenosine Receptors: Springer. 2018; pp. 515–27. doi: 10.1007/978-3-319-90808-3_21
49.
MedieroA, WilderT, Perez-AsoM, CronsteinBN. Direct or indirect stimulation of adenosine A2A receptors enhances bone regeneration as well as bone morphogenetic protein-2. FASEB J. 2015;29(4):1577–90. doi: 10.1096/fj.14-265066
50.
MorelloS, SorrentinoR, PintoA. Adenosine A2a receptor agonists as regulators of inflammation: Pharmacology and therapeutic opportunities. JRLCR. Volume. 2009;2:11–7. doi: 10.2147/jrlcr.S4710
51.
IshackS, MedieroA, WilderT, RicciJL, CronsteinBN. Bone regeneration in critical bone defects using three-dimensionally printed beta-tricalcium phosphate/hydroxyapatite scaffolds is enhanced by coating scaffolds with either dipyridamole or BMP-2. J Biomed Mater Res B Appl Biomater. 2017;105(2):366–75. doi: 10.1002/jbm.b.33561
52.
MedieroA, Perez-AsoM, CronsteinBN. Activation of adenosine A(2A) receptor reduces osteoclast formation via PKA- and ERK1/2-mediated suppression of NFkappaB nuclear translocation. Br J Pharmacol. 2013;169(6):1372–88. doi: 10.1111/bph.12227
53.
TrincavelliML, DanieleS, GiacomelliC, TalianiS, Da SettimoF, CosimelliB, et al. Osteoblast differentiation and survival: A role for A2B adenosine receptor allosteric modulators. Biochim Biophys Acta. 2014;1843(12):2957–66. doi: 10.1016/j.bbamcr.2014.09.013
54.
CarrollSH, WignerNA, KulkarniN, Johnston-CoxH, GerstenfeldLC, RavidK. A2B adenosine receptor promotes mesenchymal stem cell differentiation to osteoblasts and bone formation in vivo. J Biol Chem. 2012;287(19):15718–27. doi: 10.1074/jbc.M112.344994
55.
MontesinosMC, DesaiA, ChenJ-F, YeeH, SchwarzschildMA, FinkJS, et al. Adenosine promotes wound healing and mediates angiogenesis in response to tissue injury via occupancy of A2A receptors. Am J Pathol. 2002;160(6):2009–18. doi: 10.1016/S0002-9440(10)61151-0
56.
LeibovichSJ, ChenJ-F, Pinhal-EnfieldG, BelemPC, ElsonG, RosaniaA, et al. Synergistic up-regulation of vascular endothelial growth factor expression in murine macrophages by adenosine A2A receptor agonists and endotoxin. Am J Pathol. 2002;160(6):2231–44. doi: 10.1016/S0002-9440(10)61170-4
57.
RamakersBP, RiksenNP, RongenGA, van der HoevenJG, SmitsP, PickkersP. The effect of adenosine receptor agonists on cytokine release by human mononuclear cells depends on the specific Toll-like receptor subtype used for stimulation. Cytokine. 2006;35(1-2):95–9. doi: 10.1016/j.cyto.2006.07.014
58.
ShihYR, HwangY, PhadkeA, KangH, HwangNS, CaroEJ, et al. Calcium phosphate-bearing matrices induce osteogenic differentiation of stem cells through adenosine signaling. Proc Natl Acad Sci U S A. 2014;111(3):990–5. doi: 10.1073/pnas.1321717111
59.
BurnierM. Angiotensin II type 1 receptor blockers. Circulation. 2001;103(6):904–12. issn: 0009-7322.
60.
GebruY, DiaoTY, PanH, MukwayaE, ZhangY. Potential of RAS inhibition to improve metabolic bone disorders. Biomed Res Int. 2013;2013:932691. doi: 10.1155/2013/932691
61.
MiuraS, KarnikSS, SakuK. Review: Angiotensin II type 1 receptor blockers: Class effects versus molecular effects. J Renin Angiotensin Aldosterone Syst. 2011;12(1):1–7. doi: 10.1177/1470320310370852
62.
TamargoJ, CaballeroR, DelpónE. The Renin–Angiotensin System and Bone. Clin Rev Bone Miner Metab. 2015;13(3):125–48. doi: 10.1007/s12018-015-9189-6
63.
HaulicaI, BildW, SerbanDN. Angiotensin peptides and their pleiotropic actions. J Renin Angiotensin Aldosterone Syst. 2005;6(3):121–31. doi: 10.3317/jraas.2005.018
64.
Pérez-CastrillónJ, SilvaJ, JustoI, SanzA, Martín-LuqueroM, IgeaR, et al. Effect of quinapril, quinapril-hydrochlorothiazide, and enalapril on the bone mass of hypertensive subjects: Relationship with angiotensin converting enzyme polymorphisms. Am J Hypertens. 2003;16(6):453–9. doi: 10.1016/s0895-7061(03)00845-8
65.
YongtaoZ, KunzhengW, JingjingZ, HuS, JianqiangK, RuiyuL, et al. Glucocorticoids activate the local renin-angiotensin system in bone: Possible mechanism for glucocorticoid-induced osteoporosis. Endocrine. 2014;47(2):598–608. doi: 10.1007/s12020-014-0196-z
66.
NistalaH, Lee-ArteagaS, CartaL, CookJR, SmaldoneS, SicilianoG, et al. Differential effects of alendronate and losartan therapy on osteopenia and aortic aneurysm in mice with severe Marfan syndrome. Hum Mol Genet. 2010;19(24):4790–8. doi: 10.1093/hmg/ddq409
67.
ShimizuH, NakagamiH, OsakoMK, HanayamaR, KunugizaY, KizawaT, et al. Angiotensin II accelerates osteoporosis by activating osteoclasts. FASEB J. 2008;22(7):2465–75. doi: 10.1096/fj.07-098954
68.
ZhouY, GuanX, ChenX, YuM, WangC, ChenX, et al. Angiotensin II/Angiotensin II Receptor Blockade Affects Osteoporosis via the AT1/AT2-Mediated cAMP-Dependent PKA Pathway. Cells Tissues Organs. 2017;204(1):25–37. doi: 10.1159/000464461
69.
IzuY, MizoguchiF, KawamataA, HayataT, NakamotoT, NakashimaK, et al. Angiotensin II type 2 receptor blockade increases bone mass. J Biol Chem. 2009;284(8):4857–64. doi: 10.1074/jbc.M807610200
70.
KanekoK, ItoM, FumotoT, FukuharaR, IshidaJ, FukamizuA, et al. Physiological function of the angiotensin AT1a receptor in bone remodeling. J Bone Miner Res. 2011;26(12):2959–66. doi: 10.1002/jbmr.501
71.
GarciaP, SchwenzerS, SlottaJE, ScheuerC, TamiAE, HolsteinJH, et al. Inhibition of angiotensin-converting enzyme stimulates fracture healing and periosteal callus formation - role of a local renin-angiotensin system. Br J Pharmacol. 2010;159(8):1672–80. doi: 10.1111/j.1476-5381.2010.00651.x
72.
ShimizuH, NakagamiH, OsakoMK, NakagamiF, KunugizaY, TomitaT, et al. Prevention of osteoporosis by angiotensin-converting enzyme inhibitor in spontaneous hypertensive rats. Hypertens Res. 2009;32(9):786–90. doi: 10.1038/hr.2009.99
73.
ZhaoX, WuZX, ZhangY, GaoMX, YanYB, CaoPC, et al. Locally administrated perindopril improves healing in an ovariectomized rat tibial osteotomy model. PLoS One. 2012;7(3):e33228. doi: 10.1371/journal.pone.0033228
74.
KangKY, KangY, KimM, KimY, YiH, KimJ, et al. The effects of antihypertensive drugs on bone mineral density in ovariectomized mice. J Korean Med Sci. 2013;28(8):1139–44. doi: 10.3346/jkms.2013.28.8.1139
75.
DiaoTY, PanH, GuSS, ChenX, ZhangFY, WongMS, et al. Effects of angiotensin-converting enzyme inhibitor, captopril, on bone of mice with streptozotocin-induced type 1 diabetes. J Bone Miner Metab. 2014;32(3):261–70. doi: 10.1007/s00774-013-0500-7
76.
ZhangYF, QinL, LeungPC, KwokTC. The effect of angiotensin-converting enzyme inhibitor use on bone loss in elderly Chinese. J Bone Miner Metab. 2012;30(6):666–73. doi: 10.1007/s00774-012-0363-3
77.
DonmezBO, OzdemirS, SarikanatM, YarasN, KocP, DemirN, et al. Effect of angiotensin II type 1 receptor blocker on osteoporotic rat femurs. Pharmacol Rep. 2012;64(4):878–88. doi: 10.1016/S1734-1140(12)70882-4
78.
ZhaoX, WangJX, FengYF, WuZX, ZhangY, ShiL, et al. Systemic treatment with telmisartan improves femur fracture healing in mice. PLoS One. 2014;9(3):e92085. doi: 10.1371/journal.pone.0092085
79.
BayarA, TuranA, GülleK, AkpolatM, TuranI,
TurhanE. The effects of the angiotensin converting enzyme inhibitor Enalapril and the angiotensin II type 1 receptor blocker Losartan on fracture healing in rats. Clin Invest Med. 2015;38(4):164–72. doi: 10.25011/cim.v38i4.24261
80.
LiuJ-X, WangL, ZhangY. Involvement of Renin–Angiotensin System in Damage of Angiotensin-Converting Enzyme Inhibitor Captopril on Bone of Normal Mice. Biol Pharm Bull. 2015;38(6):869–75. doi: 10.1248/bpb.b14-00829
81.
DrakeMT, ClarkeBL, KhoslaS. Bisphosphonates: Mechanism of action and role in clinical practice. Mayo Clin Proc. 2008;83(9):1032–45. doi: 10.4065/83.9.1032
82.
RussellRG, WattsNB, EbetinoFH, RogersMJ. Mechanisms of action of bisphosphonates: Similarities and differences and their potential influence on clinical efficacy. Osteoporos Int. 2008;19(6):733–59. doi: 10.1007/s00198-007-0540-8
83.
LicataAA. Discovery, clinical development, and therapeutic uses of bisphosphonates. Ann Pharmacother. 2005;39(4):668–77. doi: 10.1345/aph.1E357
84.
HakDJ. The biology of fracture healing in osteoporosis and in the presence of anti-osteoporotic drugs. Injury. 2018;49(8):1461–5. doi: 10.1016/j.injury.2018.04.016
85.
BaussF, RussellRG. Ibandronate in osteoporosis: Preclinical data and rationale for intermittent dosing. Osteoporos Int. 2004;15(6):423–33. doi: 10.1007/s00198-004-1612-7
86.
Halasy-NagyJ, RodanG, ReszkaA. Inhibition of bone resorption by alendronate and risedronate does not require osteoclast apoptosis. Bone. 2001;29(6):553–9. doi: 10.1016/S8756-3282(01)00615-9
87.
KatesSL, Ackert-BicknellCL. How do bisphosphonates affect fracture healing?Injury. 2016;47:S65–S8. doi: 10.1016/s0020-1383(16)30015-8
88.
KobayashiY, HiragaT, UedaA, WangL, Matsumoto-NakanoM, HataK, et al. Zoledronic acid delays wound healing of the tooth extraction socket, inhibits oral epithelial cell migration, and promotes proliferation and adhesion to hydroxyapatite of oral bacteria, without causing osteonecrosis of the jaw, in mice. J Bone Miner Metab. 2010;28(2):165–75. doi: 10.1007/s00774-009-0128-9
89.
WattsNB, DiabDL. Long-term use of bisphosphonates in osteoporosis. J Clin Endocrinol Metab. 2010;95(4):1555–65. doi: 10.1210/jc.2009-1947
90.
DunfordJE, ThompsonK, CoxonFP, LuckmanSP, HahnFM, PoulterCD, et al. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharm Exp Ther. 2001;296(2):235–42. issn: 0022-3565.
91.
RussellRG. Bisphosphonates: From bench to bedside. Ann N Y Acad Sci. 2006;1068:367–401. doi: 10.1196/annals.1346.041
92.
RussellRG. Bisphosphonates: Mode of action and pharmacology. Pediatrics. 2007;119 Suppl 2:S150–62. doi: 10.1542/peds.2006-2023H
93.
JørgensenNR, SchwarzP. Effects of anti-osteoporosis medications on fracture healing. Curr Osteoporos Rep. 2011;9(3):149–55. doi: 10.1007/s11914-011-0065-0
94.
ReinholzGG, GetzB, PedersonL, SandersES, SubramaniamM, IngleJN, et al. Bisphosphonates directly regulate cell proliferation, differentiation, and gene expression in human osteoblasts. Canc Res. 2000;60(21):6001–7. issn: 0008-5472
95.
NancollasGH, TangR, PhippsRJ, HennemanZ, GuldeS, WuW, et al. Novel insights into actions of bisphosphonates on bone: Differences in interactions with hydroxyapatite. Bone. 2006;38(5):617–27. doi: 10.1016/j.bone.2005.05.003
96.
D’AmelioP, GrimaldiA, Di BellaS, TamoneC, BrianzaSZ, RavazzoliMG, et al. Risedronate reduces osteoclast precursors and cytokine production in postmenopausal osteoporotic women. J Bone Miner Res. 2008;23(3):373–9. doi: 10.1359/jbmr.071031
97.
KwakHB, KimJY, KimKJ, ChoiM-K, KimJ-J, KimKM, et al. Risedronate directly inhibits osteoclast differentiation and inflammatory bone loss. Biol Pharm Bull. 2009;32(7):1193–8. doi: 10.1248/bpb.32.1193
98.
MatosMA, TannuriU, GuarnieroR. The effect of zoledronate during bone healing. J Orthop Traumatol. 2010;11(1):7–12. doi: 10.1007/s10195-010-0083-1
99.
DunfordJE, RogersMJ, EbetinoFH, PhippsRJ, CoxonFP. Inhibition of protein prenylation by bisphosphonates causes sustained activation of Rac, Cdc42, and Rho GTPases. J Bone Miner Res. 2006;21(5):684–94. doi: 10.1359/jbmr.060118
100.
PlotkinLI, AguirreJI, KousteniS, ManolagasSC, BellidoT. Bisphosphonates and estrogens inhibit osteocyte apoptosis via distinct molecular mechanisms downstream of extracellular signal-regulated kinase activation. J Biol Chem. 2005;280(8):7317–25. doi: 10.1074/jbc.M412817200
101.
Van BeekE, LöwikC, PapapoulosS. Bisphosphonates suppress bone resorption by a direct effect on early osteoclast precursors without affecting the osteoclastogenic capacity of osteogenic cells: The role of protein geranylgeranylation in the action of nitrogencontaining bisphosphonates on osteoclast precursors. Bone. 2002;30(1):64–70. doi: 10.1016/S8756-3282(01)00655-X
102.
PapadakiHA, TsatsanisC, ChristoforidouA, MalliarakiN, PsyllakiM, PontikoglouC, et al. Alendronate reduces serum TNFalpha and IL-1beta, increases neutrophil counts, and improves bone mineral density and bone metabolism indices in patients with chronic idiopathic neutropenia (CIN)-associated osteopenia/osteoporosis. J Bone Miner Metab. 2004;22(6):577–87. doi: 10.1007/s00774-004-0526-y
103.
BellahceneA, ChapletM, BonjeanK, CastronovoV. Zoledronate inhibits alphavbeta3 and alphavbeta5 integrin cell surface expression in endothelial cells. Endothelium. 2007;14(2):123–30. doi: 10.1080/10623320701347187
104.
WoodJ, BonjeanK, RuetzS, BellahceneA, DevyL, FoidartJM, et al. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther. 2002;302(3):1055–61. doi: 10.1124/jpet.102.035295
105.
RibattiD, NicoB, MangieriD, MaruottiN, LongoV, VaccaA, et al. Neridronate inhibits angiogenesis in vitro and in vivo. Clin Rheumatol. 2007;26(7):1094–8. doi: 10.1007/s10067-006-0455-3
106.
HasmimM, BielerG, RüeggC. Zoledronate inhibits endothelial cell adhesion, migration and survival through the suppression of multiple, prenylation-dependent signaling pathways. J Thromb Haemost. 2007;5(1):166–73. doi: 10.1111/j.1538-7836.2006.02259.x
107.
StresingV, FournierPG, BellahceneA, BenzaidI, MonkkonenH, ColombelM, et al. Nitrogen-containing bisphosphonates can inhibit angiogenesis in vivo without the involvement of farnesyl pyrophosphate synthase. Bone. 2011;48(2):259–66. doi: 10.1016/j.bone.2010.09.035
108.
KangJH, ChoiNK, KangSJ, YangSY, KoHM, JungJY, et al. Alendronate affects cartilage resorption by regulating vascular endothelial growth factor expression in rats. Anat Rec (Hoboken). 2010;293(5):786–93. doi: 10.1002/ar.21092
109.
EvansK, OberbauerA. Alendronate inhibits VEGF expression in growth plate chondrocytes by acting on the mevalonate pathway. Open Orthop J. 2009;3:83. doi: 10.2174/1874325000903010083
110.
FuLJ, TangTT, HaoYQ, DaiKR. Long-term effects of alendronate on fracture healing and bone remodeling of femoral shaft in ovariectomized rats. Acta Pharmacol Sin. 2013;34(3):387–92. doi: 10.1038/aps.2012.170
111.
LiYT, CaiHF, ZhangZL. Timing of the initiation of bisphosphonates after surgery for fracture healing: A systematic review and meta-analysis of randomized controlled trials. Osteoporos Int. 2015;26(2):431–41. doi: 10.1007/s00198-014-2903-2
DelaneyMF. Strategies for the prevention and treatment of osteoporosis during early postmenopause. Am J Obstet Gynecol. 2006;194(2 Suppl):S12–23. doi: 10.1016/j.ajog.2005.08.049
114.
MolvikH, KhanW. Bisphosphonates and their influence on fracture healing: A systematic review. Osteoporos Int. 2015;26(4):1251–60. doi: 10.1007/s00198-014-3007-8
115.
KimT, HaY, KangB, LeeY, KooK. Does early administration of bisphosphonate affect fracture healing in patients with intertrochanteric fractures?J Bone Joint Surg Br. 2012;94(7):956–60. doi: 10.1302/0301-620X.94B7.29079
116.
McDonaldMM, DulaiS, GodfreyC, AmanatN, SztyndaT, LittleDG. Bolus or weekly zoledronic acid administration does not delay endochondral fracture repair but weekly dosing enhances delays in hard callus remodeling. Bone. 2008;43(4):653–62. doi: 10.1016/j.bone.2008.05.019
117.
FaucheuxC, VerronE, SoueidanA, JosseS, ArshadM, JanvierP, et al. Controlled release of bisphosphonate from a calcium phosphate biomaterial inhibits osteoclastic resorption in vitro. J Biomed Mater Res A. 2009;89(1):46–56. doi: 10.1002/jbm.a.31989
118.
MurphyCM, SchindelerA, GleesonJP, NicoleY, CantrillLC, MikulecK, et al. A collagen–hydroxyapatite scaffold allows for binding and co-delivery of recombinant bone morphogenetic proteins and bisphosphonates. Acta Biomater. 2014;10(5):2250–8. doi: 10.1016/j.actbio.2014.01.016
119.
KyllönenL, D’EsteM, AliniM, EglinD. Local drug delivery for enhancing fracture healing in osteoporotic bone. Acta Biomater. 2015;11:412–34. doi: 10.1016/j.actbio.2014.09.006
120.
YuNYC, SchindelerA, PeacockL, MikulecK, BaldockPA, RuysAJ, et al. In vivo local co-delivery of recombinant human bone morphogenetic protein-7 and pamidronate via poly-D, L-lactic acid. ECM. 2010;20:431–42. doi: 10.22203/eCM.v020a35
121.
AbassB, ShekhoH. Effects of tiludronate on healing of femoral fracture in dogs. Iraqi J Vet Sci. 2009;23. issn: 1607-3894
122.
AmanatN, McDonaldM, GodfreyC, BilstonL, LittleD. Optimal timing of a single dose of zoledronic acid to increase strength in rat fracture repair. J Bone Miner Res. 2007;22(6):867–76. doi: 10.1359/jbmr.070318
123.
LiebermanJR, DaluiskiA, EinhornTA. The role of growth factors in the repair of bone: Biology and clinical applications. JBJS. 2002;84(6):1032–44. issn: 0021-9355.
124.
VoTN, KasperFK, MikosAG. Strategies for controlled delivery of growth factors and cells for bone regeneration. Adv Drug Deliv Rev. 2012;64(12):1292–309. doi: 10.1016/j.addr.2012.01.016
125.
NauthA, RistevskiB, LiR, SchemitschEH. Growth factors and bone regeneration: How much bone can we expect?Injury. 2011;42(6):574–9. doi: 10.1016/j.injury.2011.03.034
126.
DevescoviV, LeonardiE, CiapettiG, CenniE. Growth factors in bone repair. Chir Organi Mov. 2008;92(3):161–8. doi: 10.1007/s12306-008-0064-1
127.
SagalovskyS. Physiological role of growth factors and bone morphogenetic proteins in osteogenesis and bone fracture healing: a review. Альманахклинической медицины.. 2015;38:113–126. doi: 10.18786/2072-0505-2015-38-113-126
128.
GhanbariH, Vakili-GhartavolR. Bone Regeneration: Current Status and Future Prospects. Advanced Techniques in Bone Regeneration. 2016. doi: 10.5772/63912
129.
BeamerB, HettrichC, LaneJ. Vascular endothelial growth factor: An essential component of angiogenesis and fracture healing. HSS J. 2010;6(1):85–94. doi: 10.1007/s11420-009-9129-4
130.
KeramarisN, CaloriG, NikolaouV, SchemitschE, GiannoudisP. Fracture vascularity and bone healing: A systematic review of the role of VEGF. Injury. 2008;39:S45–S57. doi: 10.1016/S0020-1383(08)70015-9
131.
HollingerJO, HartCE, HirschSN, LynchS, FriedlaenderGE. Recombinant human platelet-derived growth factor: Biology and clinical applications. JBJS. 2008;90:48–54. doi: 10.2106/JBJS.G.01231
132.
RobertsSJ, KeHZ. Anabolic Strategies to Augment Bone Fracture Healing. Curr Osteoporos Rep. 2018;16(3):289–98. doi: 10.1007/s11914-018-0440-1
133.
SuN, JinM, ChenL. Role of FGF/FGFR signaling in skeletal development and homeostasis: Learning from mouse models. Bone Res. 2014;2:14003. doi: 10.1038/boneres.2014.3
134.
SchmidGJ, KobayashiC, SandellLJ, OrnitzDM. Fibroblast growth factor expression during skeletal fracture healing in mice. Dev Dyn. 2009;238(3):766–74. doi: 10.1002/dvdy.21882
135.
DuX, XieY, XianCJ, ChenL. Role of FGFs/FGFRs in skeletal development and bone regeneration. J Cell Physiol. 2012;227(12):3731–43. doi: 10.1002/jc24083
136.
SimpsonA, MillsL, NobleB. The role of growth factors and related agents in accelerating fracture healing. Bone Joint J. 2006;88(6):701–5. doi: 10.1302/0301-620X.88B6.17524
137.
ChoTJ, GerstenfeldLC, EinhornTA. Differential temporal expression of members of the transforming growth factor β superfamily during murine fracture healing. J Bone Miner Res. 2002;17(3):513–20. doi: 10.1359/jbmr.2002.17.3.513
138.
HuangZ, NelsonER, SmithRL, GoodmanSB. The sequential expression profiles of growth factors from osteroprogenitors to osteoblasts in vitro. Tissue Eng. 2007;13(9):2311–20. doi: 10.1089/ten.2006.0423
139.
SchmidmaierG, WildemannB, GabeleinT, HeegerJ, KandzioraF, HaasNP, et al. Synergistic effect of IGF-I and TGF-beta1 on fracture healing in rats: Single versus combined application of IGF-I and TGF-beta1. Acta Orthop Scand. 2003;74(5):604–10. doi: 10.1080/00016470310018036
140.
GrahamS, LeonidouA, LesterM, HeliotisM, MantalarisA, TsiridisE. Investigating the role of PDGF as a potential drug therapy in bone formation and fracture healing. Expert Opin Investig Drugs. 2009;18(11):1633–54. doi: 10.1517/13543780903241607
141.
Al-ZubeL, BreitbartEA, O’ConnorJP, ParsonsJR, BradicaG, HartCE, et al. Recombinant human platelet-derived growth factor BB (rhPDGF-BB) and beta-tricalcium phosphate/collagen matrix enhance fracture healing in a diabetic rat model. J Orthop Res. 2009;27(8):1074–81. doi: 10.1002/jor.20842
142.
KawaguchiH, JingushiS, IzumiT, FukunagaM, MatsushitaT, NakamuraT, et al. Local application of recombinant human fibroblast growth factor-2 on bone repair: A dose-escalation prospective trial on patients with osteotomy. J Orthop Res. 2007;25(4):480–7. doi: 10.1002/jor.20315
143.
LeeK, SilvaEA, MooneyDJ. Growth factor delivery-based tissue engineering: General approaches and a review of recent developments. J R Soc Interface. 2011;8(55):153–70. doi: 10.1098/rsif.2010.0223
144.
LiR, StewartDJ, von SchroederHP, MackinnonES, SchemitschEH. Effect of cell-based VEGF gene therapy on healing of a segmental bone defect. J Orthop Res. 2009;27(1):8–14. doi: 10.1002/jor.20658
145.
GaoY, ZhuS, LuoE, LiJ, FengG, HuJ. Basic fibroblast growth factor suspended in Matrigel improves titanium implant fixation in ovariectomized rats. J Control Release. 2009;139(1):15–21. doi: 10.1016/j.jconrel.2009.05.032
146.
LiuJ, LiX, ZhangH, GuR, WangZ, GaoZ, et al. Ubiquitin E3 ligase Itch negatively regulates osteoblast function by promoting proteasome degradation of osteogenic proteins. Bone Joint Res. 2017;6(3):154–61. doi: 10.1302/2046-3758.63.BJR-2016-0237.R1
147.
GarrettIR, ChenD, GutierrezG, ZhaoM, EscobedoA, RossiniG, et al. Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro. J Clin Invest. 2003;111(11):1771–82. doi: 10.1172/jci16198
148.
LinTH, PajarinenJ, LuL, NabeshimaA, CordovaLA, YaoZ, et al. NF-kappaB as a Therapeutic Target in Inflammatory-Associated Bone Diseases. Adv Protein Chem Struct Biol. 2017;107:117–54. doi: 10.1016/bs.apcsb.2016.11.002
149.
GilmoreTD, GarbatiMR. Inhibition of NF-κB signaling as a strategy in disease therapy. NF-kB in Health and Disease: Springer. 2010, pp. 245–63. doi: 10.1007/82_2010_105
150.
PennisiA, LiX, LingW, KhanS, ZangariM, YaccobyS. The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo. Am J Hematol. 2009;84(1):6–14. doi: 10.1002/ajh.21310
151.
HuB, ChenY, UsmaniSZ, YeS, QiangW, PapanikolaouX, et al. Characterization of the molecular mechanism of the bone-anabolic activity of carfilzomib in multiple myeloma. PLoS One. 2013;8(9):e74191. doi: 10.1371/journal.pone.0074191
152.
QiangYW, HeuckCJ, ShaughnessyJDJr,
BarlogieB,
EpsteinJ. Proteasome inhibitors and bone disease. Semin Hematol. 2012;49(3):243–8. doi: 10.1053/j.seminhematol.2012.04.011
153.
GiulianiN, MorandiF, TagliaferriS, LazzarettiM, BonominiS, CrugnolaM, et al. The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients. Blood. 2007;110(1):334–8. doi: 10.1182/blood-2006-11-059188
154.
QiangYW, HuB, ChenY, ZhongY, ShiB, BarlogieB, et al. Bortezomib induces osteoblast differentiation via Wnt-independent activation of beta-catenin/TCF signaling. Blood. 2009;113(18):4319–30. doi: 10.1182/blood-2008-08-174300
155.
OyajobiBO, GarrettIR, GuptaA, FloresA, EsparzaJ, MunozS, et al. Stimulation of new bone formation by the proteasome inhibitor, bortezomib: Implications for myeloma bone disease. Br J Haematol. 2007;139(3):434–8. doi: 10.1111/j.1365-2141.2007.06829.x
156.
TerposE, HeathDJ, RahemtullaA, ZervasK, ChantryA, AnagnostopoulosA, et al. Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappaB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma. Br J Haematol. 2006;135(5):688–92. doi: 10.1111/j.1365-2141.2006.06356.x
157.
TerposE, ChristoulasD. Effects of proteasome inhibitors on bone cancer. Bonekey Rep. 2013;2:395. doi: 10.1038/bonekey.2013.129
158.
ZangariM, SuvaLJ. The effects of proteasome inhibitors on bone remodeling in multiple myeloma. Bone. 2016;86:131–8. doi: 10.1016/j.bone.2016.02.019
159.
HeiderU, KaiserM, MullerC, JakobC, ZavrskiI, SchulzCO, et al. Bortezomib increases osteoblast activity in myeloma patients irrespective of response to treatment. Eur J Haematol. 2006;77(3):233–8. doi: 10.1111/j.1600-0609.2006.00692.x
160.
MukherjeeS, RajeN, SchoonmakerJA, LiuJC, HideshimaT, WeinMN, et al. Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in mice. J Clin Invest. 2008;118(2):491–504. doi: 10.1172/JCI33102
161.
SanvoranartT, SupokawejA, KheolamaiP, YUP, KlincumhomN, ManochantrS, et al. Bortezomib enhances the osteogenic differentiation capacity of human mesenchymal stromal cells derived from bone marrow and placental tissues. Biochem Biophys Res Commun. 2014;447(4):580–5. doi: 10.1016/j.bbrc.2014.04.044
162.
KhedgikarV, KushwahaP, GautamJ, VermaA, ChangkijaB, KumarA, et al. Withaferin A: A proteasomal inhibitor promotes healing after injury and exerts anabolic effect on osteoporotic bone. Cell Death Dis. 2013;4:e778. doi: 10.1038/cddis.2013.294
163.
NagareddyPR, LakshmanaM. Withania somnifera improves bone calcification in calcium-deficient ovariectomized rats. J Pharm Pharmacol. 2006;58(4):513–9. doi: 10.1211/j58.4.0011
164.
ZangariM, YaccobyS, PappasL, CavalloF, KumarNS, RanganathanS, et al. A prospective evaluation of the biochemical, metabolic, hormonal and structural bone changes associated with bortezomib response in multiple myeloma patients. Haematologica. 2011;96(2):333–6. doi: 10.3324/haematol.2010.031302
165.
CesareoR, NapolitanoC, IozzinoM. Strontium ranelate in postmenopausal osteoporosis treatment: A critical appraisal. Int J Womens Health. 2010;2:1.
166.
AlegreDN, RibeiroC, SousaC, CorreiaJ, SilvaL, de AlmeidaL. Possible benefits of strontium ranelate in complicated long bone fractures. Rheumatol Int. 2012;32(2):439–43. doi: 10.1007/s00296-010-1687-8
167.
AmmannP, BadoudI, BarraudS, DayerR, RizzoliR. Strontium ranelate treatment improves trabecular and cortical intrinsic bone tissue quality, a determinant of bone strength. J Bone Miner Res. 2007;22(9):1419–25. doi: 10.1359/jbmr.070607
168.
BainSD, JeromeC, ShenV, Dupin-RogerI, AmmannP. Strontium ranelate improves bone strength in ovariectomized rat by positively influencing bone resistance determinants. Osteoporos Int. 2009;20(8):1417–28. doi: 10.1007/s00198-008-0815-8
169.
ChoudharyS, HalboutP, AlanderC, RaiszL, PilbeamC. Strontium ranelate promotes osteoblastic differentiation and mineralization of murine bone marrow stromal cells: Involvement of prostaglandins. J Bone Miner Res. 2007;22(7):1002–10. doi: 10.1359/jbmr.070321
170.
MariePJ, FelsenbergD, BrandiML. How strontium ranelate, via opposite effects on bone resorption and formation, prevents osteoporosis. Osteoporos Int. 2011;22(6):1659–67. doi: 10.1007/s00198-010-1369-0
171.
FromigueO, HayE, BarbaraA, MariePJ. Essential role of nuclear factor of activated T cells (NFAT)-mediated Wnt signaling in osteoblast differentiation induced by strontium ranelate. J Biol Chem. 2010;285(33):25251–8. doi: 10.1074/jbc.M110.110502
172.
FromiguéO, HaÿE, BarbaraA, PetrelC, TraiffortE, RuatM, et al. Calcium sensing receptor-dependent and receptor-independent activation of osteoblast replication and survival by strontium ranelate. J Cell Mol Med. 2009;13(8b):2189–99. doi: 10.1111/j.1582-4934.2008.00673.x
173.
AtkinsGJ, WelldonKJ, HalboutP, FindlayDM. Strontium ranelate treatment of human primary osteoblasts promotes an osteocyte-like phenotype while eliciting an osteoprotegerin response. Osteoporos Int. 2009;20(4):653–64. doi: 10.1007/s00198-008-0728-6
174.
BrennanTC, RybchynMS, GreenW, AtwaS, ConigraveAD, MasonRS. Osteoblasts play key roles in the mechanisms of action of strontium ranelate. Br J Pharmacol. 2009;157(7):1291–300. doi: 10.1111/j.1476-5381.2009.00305.x
175.
OzturanKE, DemirB, YucelI, CakiciH, YilmazF, HaberalA. Effect of strontium ranelate on fracture healing in the osteoporotic rats. J Orthop Res. 2011;29(1):138–42. doi: 10.1002/jor.21204
176.
ZhuLL, ZaidiS, PengY, ZhouH, MoongaBS, BlesiusA, et al. Induction of a program gene expression during osteoblast differentiation with strontium ranelate. Biochem Biophys Res Commun. 2007;355(2):307–11. doi: 10.1016/j.bbrc.2007.01.120
177.
YangF, YangD, TuJ, ZhengQ, CaiL, WangL. Strontium enhances osteogenic differentiation of mesenchymal stem cells and in vivo bone formation by activating Wnt/catenin signaling. Stem Cells. 2011;29(6):981–91. doi: 10.1002/stem.646
178.
PengS, ZhouG, LukKD, CheungKM, LiZ, LamWM, et al. Strontium promotes osteogenic differentiation of mesenchymal stem cells through the Ras/MAPK signaling pathway. Cell Physiol Biochem. 2009;23(1-3):165–74. doi: 10.1159/000204105
179.
SirbuPD, TudorR, VeringaV, CiuntuBM, RaduV, CiubaraB, et al. Strontium Ranelate in the Healing of Fractures Complicated with Delayed Union. It is Really Effective?Rev Chim(Bucharest). 2017;68:1825.
180.
CarvalhoNN, VossLA, AlmeidaMO, SalgadoCL, BandeiraF. Atypical femoral fractures during prolonged use of bisphosphonates: Short-term responses to strontium ranelate and teriparatide. J Clin Endocrinol Metab. 2011;96(9):2675–80. doi: 10.1210/jc.2011-0593
181.
FarlayD, BoivinG, PanczerG, LalandeA, MeunierPJ. Long-term strontium ranelate administration in monkeys preserves characteristics of bone mineral crystals and degree of mineralization of bone. J Bone Miner Res. 2005;20(9):1569–78. doi: 10.1359/JBMR.050405
182.
Henriques LourencoA, NevesN, Ribeiro-MachadoC, SousaSR, LamghariM, BarriasCC, et al. Injectable hybrid system for strontium local delivery promotes bone regeneration in a rat critical-sized defect model. Sci Rep. 2017;7(1):5098. doi: 10.1038/s41598-017-04866-4
MariePJ, AmmannP, BoivinG, ReyC. Mechanisms of Action and Therapeutic Potential of Strontium in Bone. Calcif Tissue Int. 2001;69(3):121–9. doi: 10.1007/s002230010055
185.
ThormannU, RayS, SommerU, ElkhassawnaT, RehlingT, HundgeburthM, et al. Bone formation induced by strontium modified calcium phosphate cement in critical-size metaphyseal fracture defects in ovariectomized rats. Biomaterials. 2013;34(34):8589–98. doi: 10.1016/j.biomaterials.2013.07.036
186.
ChengC, AltV, PanL, ThormannU, SchnettlerR, StraussLG, et al. Preliminary evaluation of different biomaterials for defect healing in an experimental osteoporotic rat model with dynamic PET-CT (dPET-CT) using F-18-Sodium Fluoride (NaF). Injury. 2014;45(3):501–5. doi: 10.1016/j.injury.2013.11.023
187.
HabermannB, KafchitsasK, OlenderG, AugatP, KurthA. Strontium ranelate enhances callus strength more than PTH 1-34 in an osteoporotic rat model of fracture healing. Calcif Tissue Int. 2010;86(1):82–9. doi: 10.1007/s00223-009-9317-8
188.
ScaglioneM, FabbriL, CasellaF, GuidoG. Strontium ranelate as an adjuvant for fracture healing: Clinical, radiological, and ultrasound findings in a randomized controlled study on wrist fractures. Osteoporos Int. 2016;27(1):211–8. doi: 10.1007/s00198-015-3266-z
189.
LiuF, ZhangX, YuX, XuY, FengT, RenD. In vitro study in stimulating the secretion of angiogenic growth factors of strontium-doped calcium polyphosphate for bone tissue engineering. J Mater Sci Mater Med. 2011;22(3):683–92. doi: 10.1007/s10856-011-4247-1
190.
AgholmeF, AspenbergP. Wnt signaling and orthopedics, an overview. Acta Orthop. 2011;82(2):125–30. doi: 10.3109/17453674.2011.572252
191.
ChenY, AlmanBA. Wnt pathway, an essential role in bone regeneration. J Cell Biochem. 2009;106(3):353–62. doi: 10.1002/jcb.22020
192.
MacsaiCE, FosterBK, XianCJ. Roles of Wnt signalling in bone growth, remodelling, skeletal disorders and fracture repair. J Cell Physiol. 2008;215(3):578–87. doi: 10.1002/jc21342
193.
BaoQ, ChenS, QinH, FengJ, LiuH, LiuD, et al. An appropriate Wnt/beta-catenin expression level during the remodeling phase is required for improved bone fracture healing in mice. Sci Rep. 2017;7(1):2695. doi: 10.1038/s41598-017-02705-0
194.
LeuchtP, LeeS, YimN. Wnt signaling and bone regeneration: Can’t have one without the other. Biomaterials. 2018. doi: 10.1016/j.biomaterials.2018.03.029
195.
BlagodatskiA, PoteryaevD, KatanaevVL. Targeting the Wnt pathways for therapies. Mol Cell Ther. 2014;2(1):28. doi: 10.1186/2052-8426-2-28
196.
KimJB, LeuchtP, LamK, LuppenC, Ten BergeD, NusseR, et al. Bone regeneration is regulated by wnt signaling. J Bone Miner Res. 2007;22(12):1913–23. doi: 10.1359/jbmr.070802
197.
SilkstoneD, HongH, AlmanBA. Beta-catenin in the race to fracture repair: In it to Wnt. Nat Clin Pract Rheumatol. 2008;4(8):413–9. doi: 10.1038/ncprheum0838
198.
WiseJK, SenaK, VranizanK, PollockJF, HealyKE, HughesWF, et al. Temporal gene expression profiling during rat femoral marrow ablation-induced intramembranous bone regeneration. PLoS One. 2010;5(10). doi: 10.1371/journal.pone.0012987
199.
ChenY, WhetstoneHC, LinAC, NadesanP, WeiQ, PoonR, et al. Beta-catenin signaling plays a disparate role in different phases of fracture repair: Implications for therapy to improve bone healing. PLoS medicine. 2007;4(7):e249. doi: 10.1371/journal.pmed.0040249
200.
HeilmannA, SchinkeT, BindlR, WehnerT, RappA, Haffner-LuntzerM, et al. The Wnt serpentine receptor Frizzled-9 regulates new bone formation in fracture healing. PLoS One. 2013;8(12):e84232. doi: 10.1371/journal.pone.0084232
201.
PitersE, BoudinE, Van HulW. Wnt signaling: A win for bone. Arch Biochem Biophys. 2008;473(2):112–6. doi: 10.1016/j.abb.2008.03.006
202.
WestendorfJJ, KahlerRA, SchroederTM. Wnt signaling in osteoblasts and bone diseases. Gene. 2004;341:19–39. doi: 10.1016/j.gene.2004.06.044
203.
GalliC, PasseriG, MacalusoGM. Osteocytes and WNT: The mechanical control of bone formation. J Dent Res. 2010;89(4):331–43. doi: 10.1177/0022034510363963
204.
BaronR, HesseE. Update on bone anabolics in osteoporosis treatment: Rationale, current status, and perspectives. J Clin Endocrinol Metab. 2012;97(2):311–25. doi: 10.1210/jc.2011-2332
205.
BaronR, KneisselM. WNT signaling in bone homeostasis and disease: From human mutations to treatments. Nat Med. 2013;19(2):179. doi: 10.1038/nm.3074
206.
BaronR, RawadiG. Targeting the Wnt/beta-catenin pathway to regulate bone formation in the adult skeleton. Endocrinology. 2007;148(6):2635–43. doi: 10.1210/en.2007-0270
207.
CanalisE. Wnt signalling in osteoporosis: Mechanisms and novel therapeutic approaches. Nat Rev Endocrinol. 2013;9(10):575–83. doi: 10.1038/nrendo.2013.154
208.
HoeppnerLH, SecretoFJ, WestendorfJJ. Wnt signaling as a therapeutic target for bone diseases. Expert Opin Ther Target. 2009;13(4):485–96. doi: 10.1517/14728220902841961
209.
JonesSE, JomaryC. Secreted Frizzled-related proteins: Searching for relationships and patterns. Bioessays. 2002;24(9):811–20. doi: 10.1002/bies.10136
210.
JohnsonML, KamelMA. The Wnt signaling pathway and bone metabolism. Curr Opin Rheumatol. 2007;19(4):376–82. doi: 10.1097/BOR.0b013e32816e06f9
211.
KhoslaS, WestendorfJJ, OurslerMJ. Building bone to reverse osteoporosis and repair fractures. J Clin Invest. 2008;118(2):421–8. doi: 10.1172/JCI33612
212.
KubotaT, MichigamiT, OzonoK. Wnt signaling in bone metabolism. J Bone Miner Metab. 2009;27(3):265–71. doi: 10.1007/s00774-009-0064-8
213.
KrishnanV, BryantHU, MacdougaldOA. Regulation of bone mass by Wnt signaling. J Clin Invest. 2006;116(5):1202–9. doi: 10.1172/JCI28551
214.
GlassDA2nd, KarsentyG. In vivo analysis of Wnt signaling in bone. Endocrinology. 2007;148(6):2630–4. doi: 10.1210/en.2006-1372
215.
HillTP, SpaterD, TaketoMM, BirchmeierW, HartmannC. Canonical Wnt/beta-catenin signaling prevents osteoblasts from differentiating into chondrocytes. Dev Cell. 2005;8(5):727–38. doi: 10.1016/j.devcel.2005.02.013
216.
HadjiargyrouM, LombardoF, ZhaoS, AhrensW, JooJ, AhnH, et al. Transcriptional profiling of bone regeneration. Insight into the molecular complexity of wound repair. J Biol Chem. 2002;277(33):30177–82. doi: 10.1074/jbc.M203171200
217.
HanY, YouX, XingW, ZhangZ, ZouW. Paracrine and endocrine actions of bone—the functions of secretory proteins from osteoblasts, osteocytes, and osteoclasts. Bone Res. 2018;6(1). doi: 10.1038/s41413-018-0019-6
218.
KeHZ, RichardsWG, LiX, OminskyMS. Sclerostin and Dickkopf-1 as therapeutic targets in bone diseases. Endocr Rev. 2012;33(5):747–83. doi: 10.1210/er.2011-1060
219.
MasonJJ, WilliamsBO. SOST and DKK: Antagonists of LRP Family Signaling as Targets for Treating Bone Disease. J Osteoporos. 2010;2010. doi: 10.4061/2010/460120
220.
WagnerER, ZhuG, ZhangB-Q, LuoQ, ShiQ, HuangE, et al. The therapeutic potential of the Wnt signaling pathway in bone disorders. Curr Mol Pharmacol. 2011;4(1):14–25. issn: 1874-4672.
221.
RossiniM, GattiD, AdamiS. Involvement of WNT/beta-catenin signaling in the treatment of osteoporosis. Calcif Tissue Int. 2013;93(2):121–32. doi: 10.1007/s00223-013-9749-z
222.
BaronR, RawadiG. Wnt signaling and the regulation of bone mass. Curr Osteoporos Rep. 2007;5(2):73–80. doi: 10.1007/s11914-007-0006-0
223.
BaronR, GoriF. Targeting WNT signaling in the treatment of osteoporosis. Curr Opin Pharmacol. 2018;40:134–41. doi: 10.1016/j.coph.2018.04.011
224.
WangY, NewmanMR, BenoitDS. Development of controlled drug delivery systems for bone fracture-targeted therapeutic delivery: A review. Eur J Pharm Biopharm. 2018. doi: 10.1016/j.ejpb.2018.02.023
225.
FlorioM, GunasekaranK, StolinaM, LiX, LiuL, TiptonB, et al. A bispecific antibody targeting sclerostin and DKK-1 promotes bone mass accrual and fracture repair. Nat Commun. 2016;7:11505. doi: 10.1038/ncomms11505
226.
XuH, DuanJ, NingD, LiJ, LiuR, YangR, et al. Role of Wnt signaling in fracture healing. BMB Reports. 2014;47(12):666–72. doi: 10.5483/BMBRe2014.47.12.193
227.
AgholmeF, IsakssonH, LiX, KeHZ, AspenbergP. Anti-sclerostin antibody and mechanical loading appear to influence metaphyseal bone independently in rats. Acta Orthop. 2011;82(5):628–32. doi: 10.3109/17453674.2011.625539
228.
AgholmeF, LiX, IsakssonH, KeHZ, AspenbergP. Sclerostin antibody treatment enhances metaphyseal bone healing in rats. J Bone Miner Res. 2010;25(11):2412–8. doi: 10.1002/jbmr.135
229.
AlaeeF, VirkMS, TangH, SugiyamaO, AdamsDJ, StolinaM, et al. Evaluation of the effects of systemic treatment with a sclerostin neutralizing antibody on bone repair in a rat femoral defect model. J Orthop Res. 2014;32(2):197–203. doi: 10.1002/jor.22498
230.
LinC, JiangX, DaiZ, GuoX, WengT, WangJ, et al. Sclerostin mediates bone response to mechanical unloading through antagonizing Wnt/beta-catenin signaling. J Bone Miner Res. 2009;24(10):1651–61. doi: 10.1359/jbmr.090411
231.
SuenPK, QinL. Sclerostin, an emerging therapeutic target for treating osteoporosis and osteoporotic fracture: A general review. JOT. 2016;4:1–13. doi: 10.1016/j.jot.2015.08.004
232.
MoesterMJ, PapapoulosSE, LowikCW, van BezooijenRL. Sclerostin: Current knowledge and future perspectives. Calcif Tissue Int. 2010;87(2):99-107. doi: 10.1007/s00223-010-9372-1
233.
AgholmeF, IsakssonH, KuhstossS, AspenbergP. The effects of Dickkopf-1 antibody on metaphyseal bone and implant fixation under different loading conditions. Bone. 2011;48(5):988–96. doi: 10.1016/j.bone.2011.02.008
234.
PinzoneJJ, HallBM, ThudiNK, VonauM, QiangYW, RosolTJ, et al. The role of Dickkopf-1 in bone development, homeostasis, and disease. Blood. 2009;113(3):517–25. doi: 10.1182/blood-2008-03-145169
235.
BodinePV, ZhaoW, KharodeYP, BexFJ, LambertAJ, GoadMB, et al. The Wnt antagonist secreted frizzled-related protein-1 is a negative regulator of trabecular bone formation in adult mice. Mol Endocrinol. 2004;18(5):1222–37. doi: 10.1210/me.2003-0498
236.
KawanoY, KyptaR. Secreted antagonists of the Wnt signalling pathway. J Cell Sci. 2003;116(Pt 13):2627–34. doi: 10.1242/jcs.00623
237.
EnglerTA, HenryJR, MalhotraS, CunninghamB, FurnessK, BrozinickJ, et al. Substituted 3-imidazo [1, 2-a] pyridin-3-yl-4-(1, 2, 3, 4-tetrahydro-[1, 4] diazepino-[6, 7, 1-hi] indol-7-yl) pyrrole-2, 5-diones as highly selective and potent inhibitors of glycogen synthase kinase-3. J MedChem. 2004;47(16):3934–7. doi: 10.1021/jm049768a
238.
KulkarniNH, OnyiaJE, ZengQ, TianX, LiuM, HalladayDL, et al. Orally bioavailable GSK-3alpha/beta dual inhibitor increases markers of cellular differentiation in vitro and bone mass in vivo. J Bone Miner Res. 2006;21(6):910–20. doi: 10.1359/jbmr.060316
239.
KugimiyaF, KawaguchiH, OhbaS, KawamuraN, HirataM, ChikudaH, et al. GSK-3beta controls osteogenesis through regulating Runx2 activity. PLoS One. 2007;2(9):e837. doi: 10.1371/journal.pone.0000837
240.
BennettCN, LongoKA, WrightWS, SuvaLJ, LaneTF, HankensonKD, et al. Regulation of osteoblastogenesis and bone mass by Wnt10b. Proc Natl Acad Sci USA. 2005;102(9):3324–9. doi: 10.1073/pnas.0408742102
241.
GaurT, WixtedJJ, HussainS, O’ConnellSL, MorganEF, AyersDC, et al. Secreted frizzled related protein 1 is a target to improve fracture healing. J Cell Physiol. 2009;220(1):174–81. doi: 10.1002/jc21747
242.
ReisM, LiebnerS. Wnt signaling in the vasculature. Exp Cell Res. 2013;319(9):1317–23. doi: 10.1016/j.yexcr.2012.12.023
243.
ShenX, WanC, RamaswamyG, MavalliM, WangY, DuvallCL, et al. Prolyl hydroxylase inhibitors increase neoangiogenesis and callus formation following femur fracture in mice. J Orthop Res. 2009;27(10):1298–305. doi: 10.1002/jor.20886
244.
LaurencinCT, AsheKM, HenryN, KanHM, LoKW-H. Delivery of small molecules for bone regenerative engineering: Preclinical studies and potential clinical applications. Drug Discov Today. 2014;19(6):794–800. doi: 10.1016/j.drudis.2014.01.012
245.
Victor-VegaC, DesaiA, MontesinosMC, CronsteinBN. Adenosine A2a receptor agonists promote more rapid wound healing than recombinant human platelet–derived growth factor (becaplermin gel). Inflammation. 2002;26(1):19–24. doi: 10.1023/A:1014417728325
246.
ChenX-F, LiX-L, LiuJ-X, XuJ, ZhaoY-Y, YangM, et al. Inhibition on angiotensin-converting enzyme exerts beneficial effects on trabecular bone in orchidectomized mice. Pharmacol Rep. 2018. doi: 10.1016/j.phare2018.02.008
247.
ZhangY, LiX-L, ShaN-N, ShuB, ZhaoY-J, WangX-L, et al. Differential response of bone and kidney to ACEI in db/db mice: A potential effect of captopril on accelerating bone loss. Bone. 2017;97:222–32. doi: 10.1016/j.bone.2017.01.029
248.
LiuYY, YaoWM, WuT, XuBL, ChenF, CuiL. Captopril improves osteopenia in ovariectomized rats and promotes bone formation in osteoblasts. J Bone Miner Metab. 2011;29(2):149–58. doi: 10.1007/s00774-010-0209-9
249.
BroulikP, TesarV, ZimaT, JirsaM. Impact of antihypertensive therapy on the skeleton: Effects of enalapril and AT 1 receptor antagonist losartan in female rats. Physiol Res. 2001;50(4):353–8. issn: 0862-8408.
250.
RajkumarD, FaitelsonA, GudyrevO, DubrovinG, PokrovskiM, IvanovA. Comparative evaluation of enalapril and losartan in pharmacological correction of experimental osteoporosis and fractures of its background. J Osteoporos. 2013;2013. doi: 10.1155/2013/325693
251.
MaY, StimpelM, LiangH, PunS, JeeW. Impact of antihypertensive therapy on the skeleton: Effects of moexipril and hydrochlorothiazide on osteopenia in spontaneously hypertensive ovariectomized rats. J Endocrinol. 1997;154(3):467–74. issn: 0022-0795
252.
PetersR, BeckettN, BurchL, de VernejoulMC, LiuL, DugganJ, et al. The effect of treatment based on a diuretic (indapamide)+/- ACE inhibitor (perindopril) on fractures in the Hypertension in the Very Elderly Trial (HYVET). Age Ageing. 2010;39(5):609–16. doi: 10.1093/ageing/afq071
253.
DonmezBO, UnalM, OzdemirS, OzturkN, OguzN, AkkusO. Effects of losartan treatment on the physicochemical properties of diabetic rat bone. J Bone Miner Metab. 2017;35(2):161–70. doi: 10.1007/s00774-016-0748-9
AokiM, KawahataH, SotobayashiD, YuH, MoriguchiA, NakagamiH, et al. Effect of angiotensin II receptor blocker, olmesartan, on turnover of bone metabolism in bedridden elderly hypertensive women with disuse syndrome. Geriatr Gerontol Int. 2015;15(8):1064–72. doi: 10.1111/ggi.12406
256.
KolliV, StechschulteLA, DowlingAR, RahmanS, CzernikPJ, Lecka-CzernikB. Partial agonist, telmisartan, maintains PPARgamma serine 112 phosphorylation, and does not affect osteoblast differentiation and bone mass. PLoS One. 2014;9(5):e96323. doi: 10.1371/journal.pone.0096323
257.
AySA, KaramanM, CakarM, BaltaS, ArslanE, BulucuF, et al. Amlodipine increases vitamin D levels more than valsartan in newly diagnosed hypertensive patients: pointing to an additional effect on bone metabolism or a novel marker of inflammation?Ren Fail. 2013;35(5):691–6. doi: 10.3109/0886022X.2013.780976
258.
GerstenfeldLC, SacksDJ, PelisM, MasonZD, GravesDT, BarreroM, et al. Comparison of effects of the bisphosphonate alendronate versus the RANKL inhibitor denosumab on murine fracture healing. J Bone Miner Res. 2009;24(2):196–208. doi: 10.1359/jbmr.081113
259.
XueQ, LiH, ZouX, DalstraM, LindM, ChristensenFB, et al. Alendronate treatment improves bone-pedicle screw interface fixation in posterior lateral spine fusion: An experimental study in a porcine model. Int Orthop. 2010;34(3):447–51. doi: 10.1007/s00264-009-0759-4
260.
StaalA, FrithJC, FrenchMH, SwartzJ, GüngörT, HarrityTW, et al. The Ability of Statins to Inhibit Bone Resorption Is Directly Related to Their Inhibitory Effect on HMG-CoA Reductase Activity. J Bone Miner Res. 2003;18(1):88–96. doi: 10.1359/jbmr.2003.18.1.88
261.
CaoY, MoriS, MashibaT, WestmoreMS, MaL, SatoM, et al. Raloxifene, estrogen, and alendronate affect the processes of fracture repair differently in ovariectomized rats. J Bone Miner Res. 2002;17(12):2237–46. doi: 10.1359/jbmr.2002.17.12.2237
262.
SaitoM, ShiraishiA, ItoM, SakaiS, HayakawaN, MiharaM, et al. Comparison of effects of alfacalcidol and alendronate on mechanical properties and bone collagen cross-links of callus in the fracture repair rat model. Bone. 2010;46(4):1170–9. doi: 10.1016/j.bone.2009.12.008
263.
SloanAV, MartinJR, LiS, LiJ. Parathyroid hormone and bisphosphonate have opposite effects on stress fracture repair. Bone. 2010;47(2):235–40. doi: 10.1016/j.bone.2010.05.015
264.
ArlotM, MeunierPJ, BoivinG, HaddockL, TamayoJ, Correa-RotterR, et al. Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters. J Bone Miner Res. 2005;20(7):1244–53. doi: 10.1359/JBMR.050309
265.
BauerDC, BlackDM, GarneroP, HochbergM, OttS, OrloffJ, et al. Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: The fracture intervention trial. J Bone Miner Res. 2004;19(8):1250–8. doi: 10.1359/JBMR.040512
266.
BlackDM, ThompsonDE, BauerDC, EnsrudK, MuslinerT, HochbergMC, et al. Fracture risk reduction with alendronate in women with osteoporosis: The Fracture Intervention Trial. J Clin Endocrinol Metab. 2000;85(11):4118–24. doi: 10.1210/jcem.85.11.6953
267.
BlackDM, GreenspanSL, EnsrudKE, PalermoL, McGowanJA, LangTF, et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. New Engl J Med. 2003;349(13):1207–15. doi: 10.1056/NEJMoa031975
268.
BoneHG, GreenspanSL, McKeeverC, BellN, DavidsonM, DownsRW, et al. Alendronate and estrogen effects in postmenopausal women with low bone mineral density. J Clin Endocrinol Metab. 2000;85(2):720–6. doi: 10.1210/jcem.85.2.6393
269.
BoneHG, HoskingD, DevogelaerJ-P, TucciJR, EmkeyRD, ToninoRP, et al. Ten years’ experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med. 2004;350(12):1189–99. doi: 10.1056/NEJMoa030897
270.
CeciliaD, JodarE, FernandezC, ResinesC, HawkinsF. Effect of alendronate in elderly patients after low trauma hip fracture repair. Osteoporos Int. 2009;20(6):903–10. doi: 10.1007/s00198-008-0767-z
271.
FinkelsteinJS, HayesA, HunzelmanJL, WylandJJ, LeeH, NeerRM. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med. 2003;349(13):1216–26. doi: 10.1056/NEJMoa035725
272.
GongHS, SongCH, LeeYH, RheeSH, LeeHJ, BaekGH. Early initiation of bisphosphonate does not affect healing and outcomes of volar plate fixation of osteoporotic distal radial fractures. J Bone Joint Surg Am. 2012;94(19):1729–36. doi: 10.2106/JBJS.K.01434
273.
NagahamaK, KanayamaM, TogawaD, HashimotoT, MinamiA. Does alendronate disturb the healing process of posterior lumbar interbody fusion? A prospective randomized trial. J Neurosurg Spine. 2011;14(4):500–7. doi: 10.3171/2010.11.SPINE10245
274.
OdvinaCV, ZerwekhJE, RaoDS, MaaloufN, GottschalkFA, PakCY. Severely suppressed bone turnover: A potential complication of alendronate therapy. J Clin Endocrinol Metab. 2005;90(3):1294–301. doi: 10.1210/jc.2004-0952
275.
OrwollE, EttingerM, WeissS, MillerP, KendlerD, GrahamJ, et al. Alendronate for the treatment of osteoporosis in men. N Engl J Med. 2000;343(9):604–10. doi: 10.1056/NEJM200008313430902
276.
ReckerR, MasarachiaP, SantoraA, HowardT, ChavassieuxP, ArlotM, et al. Trabecular bone microarchitecture after alendronate treatment of osteoporotic women. Curr Med Res Opin. 2005;21(2):185–94. doi: 10.1185/030079904X20259
277.
RingeJ, FaberH, DorstA. Alendronate treatment of established primary osteoporosis in men: Results of a 2-year prospective study. J Clin Endocrinol Metab. 2001;86(11):5252–5. doi: 10.1210/jcem.86.11.7988
278.
RizzoliR, LarocheM, KriegMA, FrielingI, ThomasT, DelmasP, et al. Strontium ranelate and alendronate have differing effects on distal tibia bone microstructure in women with osteoporosis. Rheumatol Int. 2010;30(10):1341–8. doi: 10.1007/s00296-010-1542-y
279.
SoininvaaraTA, JurvelinJS, MiettinenHJ, SuomalainenOT, AlhavaEM, KrogerPJ. Effect of alendronate on periprosthetic bone loss after total knee arthroplasty: A one-year, randomized, controlled trial of 19 patients. Calcif Tissue Int. 2002;71(6):472–7. doi: 10.1007/s00223-002-1022-9
280.
UchiyamaS, ItsuboT, NakamuraK, FujinagaY, SatoN, ImaedaT, et al. Effect of early administration of alendronate after surgery for distal radial fragility fracture on radiological fracture healing time. Bone Joint J. 2013;95(11):1544–50. doi: 10.1302/0301-620X.95B11.31652
281.
Van der PoestC, PatkaP, VandormaelK, HaarmanH, LipsP. The effect of alendronate on bone mass after distal forearm fracture. J Bone Miner Res. 2000;15(3):586–93. issn: 1523-4681
282.
Van der PoestC, Van EngelandM, AderH, RoosJ, PatkaP, LipsP. Alendronate in the prevention of bone loss after a fracture of the lower leg. J Bone Miner Res. 2002;17(12):2247–55. issn: 1523-4681
283.
ManabeT, MoriS, MashibaT, KajiY, IwataK, KomatsubaraS, et al. Effect of dosing interval duration of intermittent ibandronate treatment on the healing process of femoral osteotomy in a rat fracture model. Calcif Tissue Int. 2012;90(3):193–201. doi: 10.1007/s00223-011-9563-4
284.
SavaridasT, WallaceR, SalterD, SimpsonA. Do bisphosphonates inhibit direct fracture healing? A laboratory investigation using an animal model. Bone Joint J. 2013;95(9):1263–8. doi: 10.1302/0301-620X.95B9.31562
285.
ChesnutCH3rd, SkagA, ChristiansenC, ReckerR, StakkestadJA, HoisethA, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res. 2004;19(8):1241–9. doi: 10.1359/JBMR.040325
286.
ChesnutCH, EttingerMP, MillerPD, BaylinkDJ, EmkeyR, HarrisST, et al. Ibandronate produces significant, similar antifracture efficacy in North American and European women: New clinical findings from bone. Curr Med Res Opin. 2005;21(3):391–401. doi: 10.1185/030079905X30752
287.
DelmasPD, ReckerRR, ChesnutCH3rd, SkagA, StakkestadJA, EmkeyR, et al. Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: Results from the bone study. Osteoporos Int. 2004;15(10):792–8. doi: 10.1007/s00198-004-1602-9
288.
HarrisST, BlumentalsWA, MillerPD. Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: Results of a meta-analysis of phase III studies. Curr Med Res Opin. 2008;24(1):237–45. doi: 10.1185/030079908X253717
289.
McClungMR, WasnichRD, ReckerR, CauleyJA, ChesnutCH3rd, EnsrudKE, et al. Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis. J Bone Miner Res. 2004;19(1):11–8. doi: 10.1359/JBMR.0301202
290.
RingeJD, DorstA, FaberH, IbachK, SorensonF. Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: Results from a long-term comparative study. Osteoporos Int. 2003;14(10):801–7. doi: 10.1007/s00198-003-1425-0
291.
RingeJD, DorstA, FaberH, IbachK, PreussJ. Three-monthly ibandronate bolus injection offers favourable tolerability and sustained efficacy advantage over two years in established corticosteroid-induced osteoporosis. Rheumatology (Oxford). 2003;42(6):743–9. doi: 10.1093/rheumatology/keg205
292.
RingeJD, DorstA, FaberH. Effective and rapid treatment of painful localized transient osteoporosis (bone marrow edema) with intravenous ibandronate. Osteoporos Int. 2005;16(12):2063–8. doi: 10.1007/s00198-005-2001-6
293.
StakkestadJ, BenevolenskayaL, StepanJ, SkagA, NordbyA, OefjordE, et al. Intravenous ibandronate injections given every three months: A new treatment option to prevent bone loss in postmenopausal women. Ann Rheum Dis. 2003;62(10):969–75. doi: 10.1136/ard.62.10.969
294.
TankóL, FelsenbergD, CzerwińskiE, BurdeskaA, JonkanskiI, HughesC, et al. Oral weekly ibandronate prevents bone loss in postmenopausal women. J Intern Med. 2003;254(2):159–67. doi: 10.1046/j.1365-2796.2003.01174.x
295.
LiJ, MoriS, KajiY, KawanishiJ, AkiyamaT, NorimatsuH. Concentration of bisphosphonate (incadronate) in callus area and its effects on fracture healing in rats. J Bone Miner Res. 2000;15(10):2042–51. doi: 10.1359/jbmr.2000.15.10.2042
296.
LiC, MoriS, LiJ, KajiY, AkiyamaT, KawanishiJ, et al. Long-term effect of incadronate disodium (YM-175) on fracture healing of femoral shaft in growing rats. J Bone Miner Res. 2001;16(3):429–36. doi: 10.1359/jbmr.2001.16.3.429
297.
LittleDG, CornellMS, BriodyJ, CowellCT, ArbuckleS, Cooke-YarboroughCM. Intravenous pamidronate reduces osteoporosis and improves formation of the regenerate during distraction osteogenesis. J Bone Joint Surg Br. 2001;83-B(7):1069–74. doi: 10.1302/0301-620x.83b7.0831069
298.
LittleDG, CornellMS, HileMS, BriodyJ, CowellCT, BilstonL. Effect of pamidronate on distraction osteogenesis and fixator-related osteoporosis. Injury. 2001;32:14–20. doi: 10.1016/S0020-1383(01)00161-9
299.
AmanatN, BrownR, BilstonLE, LittleDG. A single systemic dose of pamidronate improves bone mineral content and accelerates restoration of strength in a rat model of fracture repair. J Orthop Res. 2005;23(5):1029–34. doi: 10.1016/j.orthres.2005.03.004
300.
MenzdorfL, WeusterM, KluterT, BruggemannS, BehrendtP, Fitchen-OesternS, et al. Local pamidronate influences fracture healing in a rodent femur fracture model: An experimental study. BMC Musculoskelet Disord. 2016;17:255. doi: 10.1186/s12891-016-1113-9
301.
LeeY-S, LowS-L, LimL-A, LokeK-Y. Cyclic pamidronate infusion improves bone mineralisation and reduces fracture incidence in osteogenesis imperfecta. Eur J Pediatr. 2001;160(11):641–4. doi: 10.1007/s004310100844
302.
LetochaAD, CintasHL, TroendleJF, ReynoldsJC, CannCE, ChernoffEJ, et al. Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement. J Bone Miner Res. 2005;20(6):977–86. doi: 10.1359/JBMR.050109
303.
MunnsCF, RauchF, ZeitlinL, FassierF, GlorieuxFH. Delayed osteotomy but not fracture healing in pediatric osteogenesis imperfecta patients receiving pamidronate. J Bone Miner Res. 2004;19(11):1779–86. doi: 10.1359/JBMR.040814
304.
AltintasF, OzkutAT, BeyzadeogluT, ErenA, GuvenM. The effect of risedronate treatment on bone turnover markers in patients with hip fracture. Acta Orthop Traumatol Turc. 2007;41(2):132–5.
305.
BrownJP, KendlerDL, McClungMR, EmkeyRD, AdachiJD, BologneseMA, et al. The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int. 2002;71(2):103–11. doi: 10.1007/s00223-002-2011-8
306.
McClungMR, GeusensP, MillerPD, ZippelH, BensenWG, RouxC, et al. Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med. 2001;344(5):333–40. doi: 10.1056/NEJM200102013440503
307.
ReginsterJ-Y, MinneH, SorensenO, HooperM, RouxC, BrandiM, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporosis Int. 2000;11(1):83–91. doi: 10.1007/s001980050010
308.
ReidDM, HughesRA, LaanRF, Sacco-GibsonNA, WenderothDH, AdamiS, et al. Efficacy and Safety of Daily Risedronate in the Treatment of Corticosteroid-Induced Osteoporosis in Men and Women: A Randomized Trial. J Bone Miner Res. 2000;15(6):1006–13. doi: 10.1359/jbmr.2000.15.6.1006
309.
WallachS, CohenS, ReidDM, HughesRA, HoskingDJ, LaanRF, et al. Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int. 2000;67(4):277–85. doi: 10.1007/s002230001146
310.
WattsNB, LindsayR, LiZ, KasibhatlaC, BrownJ. Use of matched historical controls to evaluate the anti-fracture efficacy of once-a-week risedronate. Osteoporos Int. 2003;14(5):437–41. doi: 10.1007/s00198-003-1401-8
311.
BobynJ, HackingS, KrygierJ, HarveyE, LittleD, TanzerM. Zoledronic acid causes enhancement of bone growth into porous implants. Bone Joint J. 2005;87(3):416–20. doi: 10.1302/0301-620X.87B3.14665
312.
YuYY, LieuS, HuD, MiclauT, ColnotC. Site specific effects of zoledronic acid during tibial and mandibular fracture repair. PLoS One. 2012;7(2):e31771. doi: 10.1371/journal.pone.0031771
313.
BilstonL, LittleD, SmithN, WilliamsP, BriodyJ. Zoledronic acid improves the mechanical properties of normal and healing bone. Clin Biomech. 2002;17(9):716–8. doi: 10.1016/S0268-0033(02)00108-0
314.
BransfordR, GoergensE, BriodyJ, AmanatN, CreeA, LittleD. Effect of zoledronic acid in an L6-L7 rabbit spine fusion model. Eur Spine J. 2007;16(4):557–62. doi: 10.1007/s00586-006-0212-y
315.
LittleDG, SmithNC, WilliamsPR, BriodyJN, BilstonLE, SmithEJ, et al. Zoledronic acid prevents osteopenia and increases bone strength in a rabbit model of distraction osteogenesis. J Bone Miner Res. 2003;18(7):1300–7. doi: 10.1359/jbmr.2003.18.7.1300
316.
SmithEJ, McEvoyA, LittleDG, BaldockPA, EismanJA, GardinerEM. Transient retention of endochondral cartilaginous matrix with bisphosphonate treatment in a long-term rabbit model of distraction osteogenesis. J Bone Miner Res. 2004;19(10):1698–705. doi: 10.1359/JBMR.040709
317.
GreinerSH, WildemannB, BackDA, AlidoustM, SchwabeP, HaasNP, et al. Local application of zoledronic acid incorporated in a poly(D,L-lactide)-coated implant accelerates fracture healing in rats. Acta Orthop. 2008;79(5):717–25. doi: 10.1080/17453670810016768
318.
LimSS, LeeB, KimIS, HwangSJ. Differential modulation of zoledronate and etidronate in osseous healing of an extracted socket and tibia defect. Oral Surg Oral Med Oral Pathol Oral Radiol. 2017;123(1):8–19. doi: 10.1016/j.oooo.2016.08.009
319.
LittleDG, McDonaldM, BransfordR, GodfreyCB, AmanatN. Manipulation of the anabolic and catabolic responses with OP-1 and zoledronic acid in a rat critical defect model. J Bone Miner Res. 2005;20(11):2044–52. doi: 10.1359/JBMR.050712
320.
BlackDM, DelmasPD, EastellR, ReidIR, BoonenS, CauleyJA, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. New Engl J Med. 2007;356(18):1809–22. doi: 10.1056/NEJMoa067312
321.
Colon-EmericC, NordslettenL, OlsonS, MajorN, BoonenS, HaentjensP, et al. Association between timing of zoledronic acid infusion and hip fracture healing. Osteoporos Int. 2011;22(8):2329–36. doi: 10.1007/s00198-010-1473-1
322.
HardingAK, AWD, GeijerM, Toksvig-LarsenS, TagilM. A single bisphosphonate infusion does not accelerate fracture healing in high tibial osteotomies. Acta Orthop. 2011;82(4):465–70. doi: 10.3109/17453674.2011.594231
323.
ReidIR, BrownJP, BurckhardtP, HorowitzZ, RichardsonP, TrechselU, et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med. 2002;346(9):653–61. doi: 10.1056/NEJMoa011807
324.
KoivukangasA, TuukkanenJ, KippoK, JämsäT, HannuniemiR, PasanenI, et al. Long-term administration of clodronate does not prevent fracture healing in rats. Clin Orthop Relat Res. 2003;408:268–78. doi: 10.1097/01.blo.0000043054.62337.e1
325.
AdolphsonP, AbbaszadeganH, BodenH, SalemyrM, HenriquesT. Clodronate increases mineralization of callus after Colles’ fracture: A randomized, double-blind, placebo-controlled, prospective trial in 32 patients. Acta Orthop Scand. 2000;71(2):195–200. doi: 10.1080/000164700317413193
326.
McCloskeyE, SelbyP, DaviesM, RobinsonJ, FrancisRM, AdamsJ, et al. Clodronate reduces vertebral fracture risk in women with postmenopausal or secondary osteoporosis: Results of a double-blind, placebo-controlled 3-year study. J Bone Miner Res. 2004;19(5):728–36. doi: 10.1359/JBMR.040116
327.
McCloskeyEV, BenetonM, CharlesworthD, KayanK, deTakatsD, DeyA, et al. Clodronate reduces the incidence of fractures in community-dwelling elderly women unselected for osteoporosis: Results of a double-blind, placebo-controlled randomized study. J Bone Miner Res. 2007;22(1):135–41. doi: 10.1359/jbmr.061008
328.
McCloskeyEV, JohanssonH, OdenA, VasireddyS, KayanK, PandeK, et al. Ten-year fracture probability identifies women who will benefit from clodronate therapy–additional results from a double-blind, placebo-controlled randomised study. Osteoporos Int. 2009;20(5):811–7. doi: 10.1007/s00198-008-0786-9
329.
MashibaT, TurnerC, HiranoT, ForwoodM, JacobD, JohnstonC, et al. Effects of high-dose etidronate treatment on microdamage accumulation and biomechanical properties in beagle bone before occurrence of spontaneous fractures. Bone. 2001;29(3):271–8. doi: 10.1016/S8756-3282(01)00575-0
330.
SiffledeenJS, FedorakRN, SiminoskiK, JenH, VaudanE, AbrahamN, et al. Randomized trial of etidronate plus calcium and vitamin D for treatment of low bone mineral density in Crohn’s disease. Clin Gastroenterol Hepatol. 2005;3(2):122–32. doi: 10.1016/S1542-3565(04)00663-9
331.
ParkYJ, LeeYM, LeeJY, SeolYJ, ChungCP, LeeSJ. Controlled release of platelet-derived growth factor-BB from chondroitin sulfate–chitosan sponge for guided bone regeneration. J Control Release. 2000;67(2-3):385–94. doi: 10.1016/S0168-3659(00)00232-7
332.
HollingerJO, OnikepeAO, MacKrellJ, EinhornT, BradicaG, LynchS, et al. Accelerated fracture healing in the geriatric, osteoporotic rat with recombinant human platelet-derived growth factor-BB and an injectable beta-tricalcium phosphate/collagen matrix. J Orthop Res. 2008;26(1):83–90. doi: 10.1002/jor.20453
333.
NakajimaF, NakajimaA, OgasawaraA, MoriyaH, YamazakiM. Effects of a single percutaneous injection of basic fibroblast growth factor on the healing of a closed femoral shaft fracture in the rat. Calcif Tissue Int. 2007;81(2):132–8. doi: 10.1007/s00223-007-9048-7
334.
ChenW-J, JingushiS, AoyamaI, AnzaiJ, HirataG, TamuraM, et al. Effects of FGF-2 on metaphyseal fracture repair in rabbit tibiae. J Bone Miner Metab. 2004;22(4):303–9. doi: 10.1007/s00774-003-0487-6
335.
KomakiH, TanakaT, ChazonoM, KikuchiT. Repair of segmental bone defects in rabbit tibiae using a complex of β-tricalcium phosphate, type I collagen, and fibroblast growth factor-2. Biomaterials. 2006;27(29):5118–26. doi: 10.1016/j.biomaterials.2006.05.031
336.
MaeharaH, SotomeS, YoshiiT, TorigoeI, KawasakiY, SugataY, et al. Repair of large osteochondral defects in rabbits using porous hydroxyapatite/collagen (HAp/Col) and fibroblast growth factor-2 (FGF-2). J Orthop Res. 2010;28(5):677–86. doi: 10.1002/jor.21032
337.
TakechiM, TateharaS, SatomuraK, FujisawaK, NagayamaM. Effect of FGF-2 and melatonin on implant bone healing: A histomorphometric study. J Mater Sci Mater Med. 2008;19(8):2949–52. doi: 10.1007/s10856-008-3416-3
338.
KawaguchiH, OkaH, JingushiS, IzumiT, FukunagaM, SatoK, et al. A local application of recombinant human fibroblast growth factor 2 for tibial shaft fractures: A randomized, placebo-controlled trial. J Bone Miner Res. 2010;25(12):2735–43. doi: 10.1002/jbmr.146
SchmidmaierG, WildemannB, HeegerJ, GäbeleinT, FlyvbjergA, BailH, et al. Improvement of fracture healing by systemic administration of growth hormone and local application of insulin-like growth factor-1 and transforming growth factor-β1. Bone. 2002;31(1):165–72. doi: 10.1016/S8756-3282(02)00798-6
341.
SchmidmaierG, WildemannB, OstapowiczD, KandzioraF, StangeR, HaasNP, et al. Long-term effects of local growth factor (IGF-I and TGF-β1) treatment on fracture healing: A safety study for using growth factors. J Orthop Res. 2004;22(3):514–9. doi: 10.1016/j.orthres.2003.09.009
342.
LinkDP, van den DolderJ, van den BeuckenJJ, WolkeJG, MikosAG, JansenJA. Bone response and mechanical strength of rabbit femoral defects filled with injectable CaP cements containing TGF-beta 1 loaded gelatin microparticles. Biomaterials. 2008;29(6):675–82. doi: 10.1016/j.biomaterials.2007.10.029
343.
UedaH, HongL, YamamotoM, ShigenoK, InoueM, TobaT, et al. Use of collagen sponge incorporating transforming growth factor-β1 to promote bone repair in skull defects in rabbits. Biomaterials. 2002;23(4):1003–10. doi: 10.1016/S0142-9612(01)00211-3
344.
StreetJ, BaoM, BuntingS, PealeFV, FerraraN, SteinmetzH, et al. Vascular endothelial growth factor stimulates bone repair by promoting angiogenesis and bone turnover. Proc Natl Acad Sci. 2002;99(15):9656–61. doi: 10.1073/pnas.152324099
345.
KanczlerJM, GintyPJ, BarryJJ, ClarkeNM, HowdleSM, ShakesheffKM, et al. The effect of mesenchymal populations and vascular endothelial growth factor delivered from biodegradable polymer scaffolds on bone formation. Biomaterials. 2008;29(12):1892–900. doi: 10.1016/j.biomaterials.2007.12.031
346.
MontjoventMO, LiuY, WismeijerD, HunzikerEB, SiebenrockKA, HofstetterW, et al. VEGF incorporated into calcium phosphate ceramics promotes vascularisation and bone formation in vivo. Eur Cell Mater. 2010;19:30–40. doi: 10.22203/eCM.v019a04
347.
OgilvieCM, LuC, MarcucioR, LeeM, ThompsonZ, HuD, et al. Vascular endothelial growth factor improves bone repair in a murine nonunion model. Iowa Orthop J. 2012;32:90.
348.
EckardtH, DingM, LindM, HansenES, ChristensenK, HvidI. Recombinant human vascular endothelial growth factor enhances bone healing in an experimental nonunion model. Bone Joint J. 2005;87(10):1434–8. doi: 10.1302/0301-620X.87B10.16226
349.
KleinheinzJ, StratmannU, JoosU, WiesmannH-P. VEGF-activated angiogenesis during bone regeneration. J Oral Maxillofac Surg. 2005;63(9):1310–6. doi: 10.1016/j.joms.2005.05.303
350.
KaiglerD, WangZ, HorgerK, MooneyDJ, KrebsbachPH. VEGF scaffolds enhance angiogenesis and bone regeneration in irradiated osseous defects. J Bone Miner Res. 2006;21(5):735–44. doi: 10.1359/jbmr.060120
351.
DeleuS, LemaireM, ArtsJ, MenuE, Van ValckenborghE, Vande BroekI, et al. Bortezomib alone or in combination with the histone deacetylase inhibitor JNJ-Effect on myeloma bone disease in the 5T2MM murine model of myeloma. Cancer Res. 2009;69(13):5307–11. doi: 10.1158/0008-5472.CAN-08-4472
352.
Garcia-GomezA, QuwaiderD, CanaveseM, OcioEM, TianZ, BlancoJF, et al. Preclinical activity of the oral proteasome inhibitor MLNin Myeloma bone disease. Clin Cancer Res. 2014;20(6):1542–54. doi: 10.1158/1078-0432.CCR-13-1657
353.
HurchlaMA, Garcia-GomezA, HornickMC, OcioEM, LiA, BlancoJF, et al. The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects. Leukemia. 2013;27(2):430–40. doi: 10.1038/leu.2012.183
354.
EdaH, SantoL, CirsteaDD, YeeAJ, ScullenTA, NemaniN, et al. A novel Bruton’s tyrosine kinase inhibitor CC-292 in combination with the proteasome inhibitor carfilzomib impacts the bone microenvironment in a multiple myeloma model with resultant antimyeloma activity. Leukemia. 2014;28(9):1892–901. doi: 10.1038/leu.2014.69
355.
ZavrskiI, KrebbelH, WildemannB, HeiderU, KaiserM, PossingerK, et al. Proteasome inhibitors abrogate osteoclast differentiation and osteoclast function. Biochem Biophys Res Commun. 2005;333(1):200–5. doi: 10.1016/j.bbrc.2005.05.098
356.
YoshiiT, NymanJS, YuasaM, EsparzaJM, OkawaA, GutierrezGE. Local application of a proteasome inhibitor enhances fracture healing in rats. J Orthop Res. 2015;33(8):1197–204. doi: 10.1002/jor.22849
357.
ShahrezaeeM, OryanA, BastamiF, HosseinpourS, ShahrezaeeMH, KamaliA. Comparative impact of systemic delivery of atorvastatin, simvastatin, and lovastatin on bone mineral density of the ovariectomized rats. Endocrine. 2018;60(1):138–50. doi: 10.1007/s12020-018-1531-6
358.
BertholdHK, UnverdorbenS, ZittermannA, DegenhardtR, BaumeisterB, UnverdorbenM, et al. Age-dependent effects of atorvastatin on biochemical bone turnover markers: A randomized controlled trial in postmenopausal women. Osteoporos Int. 2004;15(6):459–67. doi: 10.1007/s00198-004-1598-1
359.
BoneHG, KielDP, LindsayRS, LewieckiEM, BologneseMA, LearyET, et al. Effects of atorvastatin on bone in postmenopausal women with dyslipidemia: A double-blind, placebo-controlled, dose-ranging trial. J Clin Endocrinol Metab. 2007;92(12):4671–7. doi: 10.1210/jc.2006-1909
360.
BraatvedtG, BaggW, GambleG, DavidsonJ, ReidI. The effect of atorvastatin on markers of bone turnover in patients with type 2 diabetes. Bone. 2004;35(3):766–70. doi: 10.1016/j.bone.2004.05.001
361.
ChenZ-g, CaiH-j, JinX, LuJ-h, WangJ, FangN-y. Effects of atorvastatin on bone mineral density (BMD) and bone metabolism in elderly males with osteopenia and mild dyslipidemia: A 1-year randomized trial. Arch Gerontol Geriatr. 2014;59(3):515–21. doi: 10.1016/j.archger.2014.07.006
362.
MajimaT, KomatsuY, FukaoA, NinomiyaK, MatsumuraT, NakaoK. Short-term Effects of Atorvastatin on Bone Turnover in Male Patients with Hypercholesterolemia. Endocrine Journal. 2007;54(1):145–51. doi: 10.1507/endocrj.K06-127
363.
OhnoT, ShigetomiM, IharaK, MatsunagaT, HashimotoT, KawanoH, et al. Skeletal reconstruction by vascularized allogenic bone transplantation: Effects of statin in rats. Transplantation. 2003;76(5):869–71. doi: 10.1097/01.TP.0000074992.49236.58
364.
BenoitDS, NuttelmanCR, CollinsSD, AnsethKS. Synthesis and characterization of a fluvastatin-releasing hydrogel delivery system to modulate hMSC differentiation and function for bone regeneration. Biomaterials. 2006;27(36):6102–10. doi: 10.1016/j.biomaterials.2006.06.031
365.
BenoitDS, CollinsSD, AnsethKS. Multifunctional hydrogels that promote osteogenic hMSC differentiation through stimulation and sequestering of BMP2. Adv Funct Mater. 2007;17(13):2085–93. doi: 10.1002/adfm.200700012
366.
MoriyamaY, AyukawaY, OginoY, AtsutaI, KoyanoK. Topical application of statin affects bone healing around implants. Clin Oral Implants Res. 2008;19(6):600–5. doi: 10.1111/j.1600-0501.2007.01508.x
367.
TanabeK, NomotoH, OkumoriN, MiuraT, YoshinariM. Osteogenic effect of fluvastatin combined with biodegradable gelatin-hydrogel. Dent Mater J. 2012;31(3):489–93. doi: 10.4012/dmj.2012-008
368.
BjarnasonN, RiisB, ChristiansenC. The effect of fluvastatin on parameters of bone remodeling. Osteoporosis Int. 2001;12(5):380–4. doi: 10.1007/s001980170106
369.
BleedornJA, SullivanR, LuY, NemkeB, KalscheurV, MarkelMD. Percutaneous lovastatin accelerates bone healing but is associated with periosseous soft tissue inflammation in a canine tibial osteotomy model. J Orthop Res. 2014;32(2):210–6. doi: 10.1002/jor.22502
370.
WangW, NymanJS, MossHE, GutierrezG, MundyGR, YangX, et al. Local low-dose lovastatin delivery improves the bone-healing defect caused by Nf1 loss of function in osteoblasts. J Bone Miner Res. 2010;25(7):1658–67. doi: 10.1002/jbmr.42
GutierrezGE, LalkaD, GarrettIR, RossiniG, MundyGR. Transdermal application of lovastatin to rats causes profound increases in bone formation and plasma concentrations. Osteoporos Int. 2006;17(7):1033–42. doi: 10.1007/s00198-006-0079-0
373.
GutierrezGE, EdwardsJR, GarrettIR, NymanJS, McCluskeyB, RossiniG, et al. Transdermal lovastatin enhances fracture repair in rats. J Bone Miner Res. 2008;23(11):1722–30. doi: 10.1359/jbmr.080603
374.
IbrahimN, KhamisMF, Mod YunohMF, AbdullahS, MohamedN, ShuidAN. Targeted delivery of lovastatin and tocotrienol to fracture site promotes fracture healing in osteoporosis model: Micro-computed tomography and biomechanical evaluation. PLoS One. 2014;9(12):e115595. doi: 10.1371/journal.pone.0115595
375.
YoshiiT, HafemanAE, NymanJS, EsparzaJM, ShinomiyaK, SpenglerDM, et al. A sustained release of lovastatin from biodegradable, elastomeric polyurethane scaffolds for enhanced bone regeneration. Tissue Eng Part A. 2010;16(7):2369–79. doi: 10.1089/ten.tea.2009.0585
376.
YoshiiT, HafemanAE, EsparzaJM, OkawaA, GutierrezG, GuelcherSA. Local injection of lovastatin in biodegradable polyurethane scaffolds enhances bone regeneration in a critical-sized segmental defect in rat femora. J Tissue Eng Regen Med. 2012;8(8):589–95. doi: 10.1002/term.1547
377.
SafaeiH, JanghorbaniM, AminorroayaA, AminiM. Lovastatin effects on bone mineral density in postmenopausal women with type 2 diabetes mellitus. Acta Diabetol. 2007;44(2):76–82. doi: 10.1007/s00592-007-0246-6
378.
MajimaT, ShimatsuA, KomatsuY, SatohN, FukaoA, NinomiyaK, et al. Short-term Effects of Pitavastatin on Biochemical Markers of Bone Turnover in Patients with Hypercholesterolemia. Internal Medicine. 2007;46(24):1967–74. doi: 10.2169/internalmedicine.46.0419
379.
ReidIR, HagueW, EmbersonJ, BakerJ, TonkinA, HuntD, et al. Effect of pravastatin on frequency of fracture in the LIPID study: Secondly analysis of a randomised controlled trial. The Lancet. 2001;357(9255):509–12. doi: 10.1016/s0140-6736(00)04042-3
380.
RosensonRS, TangneyCC, LangmanCB, ParkerTS, LevineDM, GordonBR. Short-term reduction in bone markers with high-dose simvastatin. Osteoporos Int. 2005;16(10):1272–6. doi: 10.1007/s00198-005-1897-1
381.
IbrahimHK, FahmyRH. Localized rosuvastatin via implantable bioerodible sponge and its potential role in augmenting bone healing and regeneration. Drug Deliv. 2016;23(9):3181–92. doi: 10.3109/10717544.2016.1160458
382.
TürerA, DurmuslarMC, SenerI, MisirAF, OngerME. The Effect of Local Rosuvastatin on Mandibular Fracture Healing. J Craniofac Surg. 2016;27(8):e758–e61. doi: 10.1097/SCS.0000000000003120
383.
TürerA, TürerçC, DurmuşlarMC, BalliU, öngerME. The influence of oral administration of rosuvastatin on calvarial bone healing in rats. J Craniomaxillofac Surg. 2016;44(9):1327–32. doi: 10.1016/j.jcms.2016.04.021
384.
KanazawaI, YamaguchiT, YamauchiM, SugimotoT. Rosuvastatin Increased Serum Osteocalcin Levels Independent of Its Serum Cholesterol-Lowering Effect in Patients with Type 2 Diabetes and Hypercholesterolemia. Internal Medicine. 2009;48(21):1869–73. doi: 10.2169/internalmedicine.48.2645
385.
JiaZ, ZhangY, ChenYH, DusadA, YuanH, RenK, et al. Simvastatin prodrug micelles target fracture and improve healing. J Control Release. 2015;200:23–34. doi: 10.1016/j.jconrel.2014.12.028
386.
SkoglundB, ForslundC, AspenbergP. Simvastatin improves fracture healing in mice. J Bone Miner Res. 2002;17(11):2004–8. doi: 10.1359/jbmr.2002.17.11.2004
Von StechowD, FishS, YahalomD, BabI, ChorevM, MüllerR, et al. Does simvastatin stimulate bone formation in vivo?BMC Musculoskelet Disord. 2003;4(1):8. doi: 10.1186/1471-2474-4-8
389.
ZhangY, JiaZ, YuanH, DusadA, RenK, WeiX, et al. The Evaluation of Therapeutic Efficacy and Safety Profile of Simvastatin Prodrug Micelles in a Closed Fracture Mouse Model. Pharm Res. 2016;33(8):1959–71. doi: 10.1007/s11095-016-1932-2
390.
BaeMS, YangDH, LeeJB, HeoDN, KwonY-D, YounIC, et al. Photo-cured hyaluronic acid-based hydrogels containing simvastatin as a bone tissue regeneration scaffold. Biomaterials. 2011;32(32):8161–71. doi: 10.1016/j.biomaterials.2011.07.045
391.
ChissasD, StamatopoulosG, VerettasD, KazakosK, PapaloisA, AgrogiannisG, et al. Can low doses of simvastatin enhance fracture healing? An experimental study in rabbits. Injury. 2010;41(7):687–92. doi: 10.1016/j.injury.2009.10.011
392.
GaoS, ShiotaM, FujiiM, ChenK, ShimogishiM, SatoM, et al. Combination of simvastatin and hydroxyapatite fiber induces bone augmentation. Open J Regen Med. 2013;02(03):53–60. doi: 10.4236/ojrm.2013.23009
393.
HuangX, HuangZ, LiW. Highly efficient release of simvastatin from simvastatin-loaded calcium sulphate scaffolds enhances segmental bone regeneration in rabbits. Mol Med Rep. 2014;9(6):2152–8. doi: 10.3892/mmr.2014.2101
394.
SarafS, SinghA, GarbyalR, SinghV. Effect of simvastatin on fracture healing—an experimental study. 2007. issn: 0975-1009.
395.
WongRW, RabieABM. Early healing pattern of statin-induced osteogenesis. Br J Oral Maxillofac Surg. 2005;43(1):46–50. doi: 10.1016/j.bjoms.2004.08.014
396.
AnbinderAL, JunqueiraJC, ManciniMNG, BalducciI, RochaRFd, CarvalhoYR. Influence of simvastatin on bone regeneration of tibial defects and blood cholesterol level in rats. Braz Dent J. 2006;17(4):267–73. doi: 10.1590/S0103-64402006000400001
397.
AyukawaY, YasukawaE, MoriyamaY, OginoY, WadaH, AtsutaI, et al. Local application of statin promotes bone repair through the suppression of osteoclasts and the enhancement of osteoblasts at bone-healing sites in rats. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2009;107(3):336–42. doi: 10.1016/j.tripleo.2008.07.013
398.
AyukawaY, OginoY, MoriyamaY, AtsutaI, JinnoY, KiharaM, et al. Simvastatin enhances bone formation around titanium implants in rat tibiae. J Oral Rehabil. 2010;37(2):123–30. doi: 10.1111/j.1365-2842.2009.02011.x
399.
DuZ, ChenJ, YanF, XiaoY. Effects of Simvastatin on bone healing around titanium implants in osteoporotic rats. Clin Oral Implant Res. 2009;20(2):145–50. doi: 10.1111/j.1600-0501.2008.01630.x
400.
JunqueiraJC, ManciniMN, CarvalhoYR, AnbinderAL, BalducciI, RochaRF. Effects of simvastatin on bone regeneration in the mandibles of ovariectomized rats and on blood cholesterol levels. J Oral Sci. 2002;44(3-4):117–24. doi: 10.2334/josnusd.44.117
401.
LeeY, SchmidMJ, MarxDB, BeattyMW, CullenDM, CollinsME, et al. The effect of local simvastatin delivery strategies on mandibular bone formation in vivo. Biomaterials. 2008;29(12):1940–9. doi: 10.1016/j.biomaterials.2007.12.045
402.
MaB, ClarkeSA, BrooksRA, RushtonN. The effect of simvastatin on bone formation and ceramic resorption in a peri-implant defect model. Acta Biomater. 2008;4(1):149–55. doi: 10.1016/j.actbio.2007.05.004
403.
NyanM, SatoD, OdaM, MachidaT, KobayashiH, NakamuraT, et al. Bone Formation With the Combination of Simvastatin and Calcium Sulfate in Critical-Sized Rat Calvarial Defect. J Pharmacol Sci. 2007;104(4):384–6. doi: 10.1254/jphs.SC0070184
404.
OxlundH, DalstraM, AndreassenTT. Statin Given Perorally to Adult Rats Increases Cancellous Bone Mass and Compressive Strength. Calcif Tissue Int. 2001;69(5):299–304. doi: 10.1007/s00223-001-2027-5
405.
özeçI, KiliçE, GümüsC, GözeF. Effect of local simvastatin application on mandibular defects. J Craniofac Surg. 2007;18(3):546–50. doi: 10.1097/scs.0b013e318052ff05
406.
PaulyS, LuttoschF, MorawskiM, HaasN, SchmidmaierG, WildemannB. Simvastatin locally applied from a biodegradable coating of osteosynthetic implants improves fracture healing comparable to BMP-2 application. Bone. 2009;45(3):505–11. doi: 10.1016/j.bone.2009.05.010
407.
PaulyS, BackDA, KaepplerK, HaasNP, SchmidmaierG, WildemannB. Influence of statins locally applied from orthopedic implants on osseous integration. BMC Musculoskelet Disord. 2012;13(1):208. doi: 10.1186/1471-2474-13-208
408.
PişkinE, IşoğluİA,
BölgenN,
VargelI,
GriffithsS,
çavuşoğluT, et al. In vivo performance of simvastatin-loaded electrospun spiral-wound polycaprolactone scaffolds in reconstruction of cranial bone defects in the rat model. J Biomed Mater Res A. 2009;90(4):1137–51. doi: 10.1002/jbm.a.32157
409.
SteinD, LeeY, SchmidMJ, KillpackB, GenrichMA, NarayanaN, et al. Local simvastatin effects on mandibular bone growth and inflammation. J Periodontol. 2005;76(11):1861–70. doi: 10.1902/jo2005.76.11.1861
410.
VasconcelosJW, LeiteLMdS, VasconcelosGdA, AraujoIMSM, FerroLSG. Evaluation of Simvastatin in the Process of Fracture Healing in Tibiae of Rats. Rev Bras Ortop (English Edition). 2013;48(2):191–5. doi: 10.1016/j.rboe.2012.10.003
411.
WangJW, XuSW, YangDS, LvRK. Locally applied simvastatin promotes fracture healing in ovariectomized rat. Osteoporosis Int. 2007;18(12):1641–50. doi: 10.1007/s00198-007-0412-2
412.
LupattelliG, ScarponiAM, VaudoG, SiepiD, RosciniAR, GemelliF, et al. Simvastatin increases bone mineral density in hypercholesterolemic postmenopausal women. Metabolism. 2004;53(6):744–8. doi: 10.1016/j.metabol.2004.01.010
413.
MontagnaniA, GonnelliS, CepollaroC, PaciniS, CampagnaM, FranciM, et al. Effect of simvastatin treatment on bone mineral density and bone turnover in hypercholesterolemic postmenopausal women: A 1-year longitudinal study. Bone. 2003;32(4):427–33. doi: 10.1016/S8756-3282(03)00034-6
414.
PatilS, HoltG, RabyN, McLellanAR, SmithK, O’KaneS, et al. Prospective, double blind, randomized, controlled trial of simvastatin in human fracture healing. J Orthop Res. 2009;27(3):281–5. doi: 10.1002/jor.20572
415.
RejnmarkL, BuusNH, VestergaardP, HeickendorffL, AndreasenF, LarsenML, et al. Effects of simvastatin on bone turnover and BMD: A 1-year randomized controlled trial in postmenopausal osteopenic women. J Bone Miner Res. 2004;19(5):737–44. doi: 10.1359/JBMR.040209
416.
TikizC, TikizH, TaneliF, GumuserG, TuzunC. Effects of simvastatin on bone mineral density and remodeling parameters in postmenopausal osteopenic subjects: 1-year follow-up study. Clin Rheumatol. 2005;24(5):447–52. doi: 10.1007/s10067-004-1053-x
417.
SchumacherM, LodeA, HelthA, GelinskyM. A novel strontium (II)-modified calcium phosphate bone cement stimulates human-bone-marrow-derived mesenchymal stem cell proliferation and osteogenic differentiation in vitro. Acta Biomater. 2013;9(12):9547–57. doi: 10.1016/j.actbio.2013.07.027
418.
CapucciniC, TorricelliP, BoaniniE, GazzanoM, GiardinoR, BigiA. Interaction of Sr-doped hydroxyapatite nanocrystals with osteoclast and osteoblast-like cells. J Biomed Mater Res A. 2009;89(3):594–600. doi: 10.1002/jbm.a.31975
419.
XueW, MooreJL, HosickHL, BoseS, BandyopadhyayA, LuW, et al. Osteoprecursor cell response to strontium-containing hydroxyapatite ceramics. J Biomed Mater Res A. 2006;79(4):804–14. doi: 10.1002/jbm.a.30815
420.
XueW, HosickHL, BandyopadhyayA, BoseS, DingC, LukKDK, et al. Preparation and cell–materials interactions of plasma sprayed strontium-containing hydroxyapatite coating. Surf Coat Tech. 2007;201(8):4685–93. doi: 10.1016/j.surfcoat.2006.10.012
421.
FuDL, JiangQH, HeFM, YangGL, LiuL. Fluorescence microscopic analysis of bone osseointegration of strontium-substituted hydroxyapatite implants. J Zhejiang Univ Sci B. 2012;13(5):364–71. doi: 10.1631/jzus.B1100381
422.
WongC, LuW, ChanW, CheungK, LukK, LuD, et al. In vivo cancellous bone remodeling on a strontium-containing hydroxyapatite (sr-HA) bioactive cement. J Biomed Mater Res A. 2004;68(3):513–21. doi: 10.1002/jbm.a.20089
423.
YanJ, SunJF, ChuPK, HanY, ZhangYM. Bone integration capability of a series of strontium-containing hydroxyapatite coatings formed by micro-arc oxidation. J Biomed Mater Res A. 2013;101(9):2465–80. doi: 10.1002/jbm.a.34548
424.
LiY, LiQ, ZhuS, LuoE, LiJ, FengG, et al. The effect of strontium-substituted hydroxyapatite coating on implant fixation in ovariectomized rats. Biomaterials. 2010;31(34):9006–14. doi: 10.1016/j.biomaterials.2010.07.112
425.
TaoZ, ZhouW, JiangY, WuX, XuZ, YangM, et al. Effects of strontium-modified calcium phosphate cement combined with bone morphogenetic protein-2 on osteoporotic bone defects healing in rats. J Biomater Appl. 2018;33(1):3–10. doi: 10.1177/0885328218765847
426.
YangS, WangL, FengS, YangQ, YuB, TuM. Enhanced bone formation by strontium modified calcium sulfate hemihydrate in ovariectomized rat critical-size calvarial defects. Biomed Mater. 2017;12(3):035004. doi: 10.1088/1748-605X/aa68bc
427.
ReitmaierS, KovtunA, SchuelkeJ, KanterB, LemmM, HoessA, et al. Strontium(II) and mechanical loading additively augment bone formation in calcium phosphate scaffolds. J Orthop Res. 2018;36(1):106–17. doi: 10.1002/jor.23623
428.
BuehlerJ, ChappuisP, SaffarJ, TsouderosY, VigneryA. Strontium ranelate inhibits bone resorption while maintaining bone formation in alveolar bone in monkeys (Macaca fascicularis). Bone. 2001;29(2):176–9. doi: 10.1016/S8756-3282(01)00484-7
429.
IbrahimMR, SinghS, MericanAM, RaghavendranHR, MuraliMR, NaveenSV, et al. The effect of strontium ranelate on the healing of a fractured ulna with bone gap in rabbit. BMC Vet Res. 2016;12(1):112. doi: 10.1186/s12917-016-0724-6
430.
Álvarez-LloretP, FernandezJM, MolinuevoMS, LinoAB, FerrettiJL, CapozzaRF, et al. Multi-Scale Approach for the Evaluation of Bone Mineralization in Strontium Ranelate-Treated Diabetic Rats. Biol Trace Elem Res. 2018;186(2):457–66. doi: 10.1007/s12011-018-1322-1
431.
BoydSK, SzaboE, AmmannP. Increased bone strength is associated with improved bone microarchitecture in intact female rats treated with strontium ranelate: A finite element analysis study. Bone. 2011;48(5):1109–16. doi: 10.1016/j.bone.2011.01.004
432.
BrüelA, OlsenJ, BirkedalH, RisagerM, AndreassenTT, RaffaltAC, et al. Strontium is incorporated into the fracture callus but does not influence the mechanical strength of healing rat fractures. Calcif Tissue Int. 2011;88(2):142–52. doi: 10.1007/s00223-010-9439-z
433.
CaoGL, TianFM, LiuGY, SongHP, YuanLL, GengLD, et al. Strontium Ranelate Combined with Insulin Is as Beneficial as Insulin Alone in Treatment of Fracture Healing in Ovariectomized Diabetic Rats. Med Sci Monit. 2018;24:6525–36. doi: 10.12659/MSM.911573
434.
CebesoyO, TutarE, KoseKC, BaltaciY, BagciC. Effect of strontium ranelate on fracture healing in rat tibia. Joint bone spine. 2007;74(6):590–3. doi: 10.1016/j.jbspin.2007.01.034
435.
LavetC, MabilleauG, ChappardD, RizzoliR, AmmannP. Strontium ranelate stimulates trabecular bone formation in a rat tibial bone defect healing process. Osteoporos Int. 2017;28(12):3475–87. doi: 10.1007/s00198-017-4156-3
436.
MaYL, ZengQQ, PorrasLL, HarveyA, MooreTL, ShelbournTL, et al. Teriparatide [rhPTH (1-34)], but not strontium ranelate, demonstrated bone anabolic efficacy in mature, osteopenic, ovariectomized rats. Endocrinology. 2011;152(5):1767–78. doi: 10.1210/en.2010-1112
437.
ZacchettiG, DayerR, RizzoliR, AmmannP. Systemic treatment with strontium ranelate accelerates the filling of a bone defect and improves the material level properties of the healing bone. Biomed Res Int. 2014;2014:549785. doi: 10.1155/2014/549785
438.
ArlotME, JiangY, GenantHK, ZhaoJ, Burt-PichatB, RouxJP, et al. Histomorphometric and microCT analysis of bone biopsies from postmenopausal osteoporotic women treated with strontium ranelate. J Bone Miner Res. 2008;23(2):215–22. doi: 10.1359/jbmr.071012
439.
MeunierPJ, RouxC, SeemanE, OrtolaniS, BadurskiJE, SpectorTD, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med. 2004;350(5):459–68. doi: 10.1056/NEJMoa022436
440.
ReckerRR, MarinF, Ish-ShalomS, MorickeR, HawkinsF, KapetanosG, et al. Comparative effects of teriparatide and strontium ranelate on bone biopsies and biochemical markers of bone turnover in postmenopausal women with osteoporosis. J Bone Miner Res. 2009;24(8):1358–68. doi: 10.1359/jbmr.090315
441.
GentlemanE, FredholmYC, JellG, LotfibakhshaieshN, O’DonnellMD, HillRG, et al. The effects of strontium-substituted bioactive glasses on osteoblasts and osteoclasts in vitro. Biomaterials. 2010;31(14):3949–56. doi: 10.1016/j.biomaterials.2010.01.121
442.
ZreiqatH, RamaswamyY, WuC, PaschalidisA, LuZ, JamesB, et al. The incorporation of strontium and zinc into a calcium–silicon ceramic for bone tissue engineering. Biomaterials. 2010;31(12):3175–84. doi: 10.1016/j.biomaterials.2010.01.024
443.
YuHM, JerchowB, SheuTJ, LiuB, CostantiniF, PuzasJE, et al. The role of Axin2 in calvarial morphogenesis and craniosynostosis. Development. 2005;132(8):1995–2005. doi: 10.1242/dev.01786
444.
DiarraD, StolinaM, PolzerK, ZwerinaJ, OminskyMS, DwyerD, et al. Dickkopf-1 is a master regulator of joint remodeling. Nat Med. 2007;13(2):156–63. doi: 10.1038/nm1538
445.
GlantschnigH, HamptonRA, LuP, ZhaoJZ, VitelliS, HuangL, et al. Generation and selection of novel fully human monoclonal antibodies that neutralize Dickkopf-1 (DKK1) inhibitory function in vitro and increase bone mass in vivo. J Biol Chem. 2010;285(51):40135–47. doi: 10.1074/jbc.M110.166892
446.
GlantschnigH, ScottK, HamptonR, WeiN, McCrackenP, NantermetP, et al. A rate-limiting role for Dickkopf-1 in bone formation and the remediation of bone loss in mouse and primate models of postmenopausal osteoporosis by an experimental therapeutic antibody. J Pharmacol Exp Ther. 2011;338(2):568–78. doi: 10.1124/jpet.111.181404
447.
HeilandGR, ZwerinaK, BaumW, KirevaT, DistlerJH, GrisantiM, et al. Neutralisation of Dkk-1 protects from systemic bone loss during inflammation and reduces sclerostin expression. Ann Rheum Dis. 2010;69(12):2152–9. doi: 10.1136/ard.2010.132852
448.
JinH, WangB, LiJ, XieW, MaoQ, LiS, et al. Anti-DKK1 antibody promotes bone fracture healing through activation of beta-catenin signaling. Bone. 2015;71:63–75. doi: 10.1016/j.bone.2014.07.039
LiX, GrisantiM, FanW, AsuncionFJ, TanHL, DwyerD, et al. Dickkopf-1 regulates bone formation in young growing rodents and upon traumatic injury. J Bone Miner Res. 2011;26(11):2610–21. doi: 10.1002/jbmr.472
451.
MacDonaldBT, JoinerDM, OysermanSM, SharmaP, GoldsteinSA, HeX, et al. Bone mass is inversely proportional to Dkk1 levels in mice. Bone. 2007;41(3):331–9. doi: 10.1016/j.bone.2007.05.009
452.
MorvanF, BoulukosK, Clement-LacroixP, Roman RomanS, Suc-RoyerI, VayssiereB, et al. Deletion of a single allele of the Dkk1 gene leads to an increase in bone formation and bone mass. J Bone Miner Res. 2006;21(6):934–45. doi: 10.1359/jbmr.060311
453.
LiJ, SarosiI, CattleyRC, PretoriusJ, AsuncionF, GrisantiM, et al. Dkk1-mediated inhibition of Wnt signaling in bone results in osteopenia. Bone. 2006;39(4):754–66. doi: 10.1016/j.bone.2006.03.017
454.
YaoGQ, WuJJ, TroianoN, InsognaK. Targeted overexpression of Dkk1 in osteoblasts reduces bone mass but does not impair the anabolic response to intermittent PTH treatment in mice. J Bone Miner Metab. 2011;29(2):141–8. doi: 10.1007/s00774-010-0202-3
455.
GambardellaA, NagarajuCK, O’SheaPJ, MohantyST, KottamL, PillingJ, et al. Glycogen synthase kinase-3alpha/beta inhibition promotes in vivo amplification of endogenous mesenchymal progenitors with osteogenic and adipogenic potential and their differentiation to the osteogenic lineage. J Bone Miner Res. 2011;26(4):811–21. doi: 10.1002/jbmr.266
456.
MarsellR, SisaskG, NilssonY, Sundgren-AnderssonAK, AnderssonU, LarssonS, et al. GSK-3 inhibition by an orally active small molecule increases bone mass in rats. Bone. 2012;50(3):619–27. doi: 10.1016/j.bone.2011.11.007
457.
SisaskG, MarsellR, Sundgren-AnderssonA, LarssonS, NilssonO, Ljunggrenö, et al. Rats treated with AZDa GSK3 inhibitor, heal fractures rapidly without endochondral bone formation. Bone. 2013;54(1):126–32. doi: 10.1016/j.bone.2013.01.019
458.
Clément-LacroixP, AiM, MorvanF, Roman-RomanS, VayssièreB, BellevilleC, et al. Lrp5-independent activation of Wnt signaling by lithium chloride increases bone formation and bone mass in mice. Proc Natl Acad Sci USA. 2005;102(48):17406–11. doi: 10.1073/pnas.0505259102
ZamaniA, OmraniGR, NasabMM. Lithium’s effect on bone mineral density. Bone. 2009;44(2):331–4. doi: 10.1016/j.bone.2008.10.001
461.
AlzahraniMM, RauchF, HamdyRC. Does Sclerostin Depletion Stimulate Fracture Healing in a Mouse Model?Clin Orthop Relat Res. 2016;474(5):1294–302. doi: 10.1007/s11999-015-4640-z
462.
JawadMU, FrittonKE, MaT, RenPG, GoodmanSB, KeHZ, et al. Effects of sclerostin antibody on healing of a non-critical size femoral bone defect. J Orthop Res. 2013;31(1):155–63. doi: 10.1002/jor.22186
463.
SpatzJM, EllmanR, CloutierAM, LouisL, van VlietM, SuvaLJ, et al. Sclerostin antibody inhibits skeletal deterioration due to reduced mechanical loading. J Bone Miner Res. 2013;28(4):865–74. doi: 10.1002/jbmr.1807
464.
YeeCS, XieL, HatsellS, HumN, MurugeshD, EconomidesAN, et al. Sclerostin antibody treatment improves fracture outcomes in a Type I diabetic mouse model. Bone. 2016;82:122–34. doi: 10.1016/j.bone.2015.04.048
465.
OminskyMS, VlasserosF, JoletteJ, SmithSY, StouchB, DoellgastG, et al. Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength. J Bone Miner Res. 2010;25(5):948–59. doi: 10.1002/jbmr.14
466.
OminskyMS, LiC, LiX, TanHL, LeeE, BarreroM, et al. Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of nonfractured bones. J Bone Miner Res. 2011;26(5):1012–21. doi: 10.1002/jbmr.307
467.
HamannC, RaunerM, HohnaY, BernhardtR, MettelsiefenJ, GoettschC, et al. Sclerostin antibody treatment improves bone mass, bone strength, and bone defect regeneration in rats with type 2 diabetes mellitus. J Bone Miner Res. 2013;28(3):627–38. doi: 10.1002/jbmr.1803
468.
LiX, OminskyMS, WarmingtonKS, MoronyS, GongJ, CaoJ, et al. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res. 2009;24(4):578–88. doi: 10.1359/jbmr.081206
469.
LiX, WarmingtonKS, NiuQT, AsuncionFJ, BarreroM, GrisantiM, et al. Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass, and bone strength in aged male rats. J Bone Miner Res. 2010;25(12):2647–56. doi: 10.1002/jbmr.182
470.
LiX, OminskyMS, WarmingtonKS, NiuQT, AsuncionFJ, BarreroM, et al. Increased bone formation and bone mass induced by sclerostin antibody is not affected by pretreatment or cotreatment with alendronate in osteopenic, ovariectomized rats. Endocrinology. 2011;152(9):3312–22. doi: 10.1210/en.2011-0252
471.
LiuS, VirdiAS, SenaK, SumnerDR. Sclerostin antibody prevents particle-induced implant loosening by stimulating bone formation and inhibiting bone resorption in a rat model. Arthritis Rheum. 2012;64(12):4012–20. doi: 10.1002/art.37697
472.
McDonaldMM, MorseA, MikulecK, PeacockL, YuN, BaldockPA, et al. Inhibition of sclerostin by systemic treatment with sclerostin antibody enhances healing of proximal tibial defects in ovariectomized rats. J Orthop Res. 2012;30(10):1541–8. doi: 10.1002/jor.22109
473.
SuenPK, HeYX, ChowDH, HuangL, LiC, KeHZ, et al. Sclerostin monoclonal antibody enhanced bone fracture healing in an open osteotomy model in rats. J Orthop Res. 2014;32(8):997–1005. doi: 10.1002/jor.22636
474.
TianX, SetterbergRB, LiX, PasztyC, KeHZ, JeeWS. Treatment with a sclerostin antibody increases cancellous bone formation and bone mass regardless of marrow composition in adult female rats. Bone. 2010;47(3):529–33. doi: 10.1016/j.bone.2010.05.032
475.
TianX, JeeWS, LiX, PasztyC, KeHZ. Sclerostin antibody increases bone mass by stimulating bone formation and inhibiting bone resorption in a hindlimb-immobilization rat model. Bone. 2011;48(2):197–201. doi: 10.1016/j.bone.2010.09.009
476.
VirkMS, AlaeeF, TangH, OminskyMS, KeHZ, LiebermanJR. Systemic administration of sclerostin antibody enhances bone repair in a critical-sized femoral defect in a rat model. J Bone Joint Surg Am. 2013;95(8):694–701. doi: 10.2106/JBJS.L.00285
477.
McColmJ, HuL, WomackT, TangCC, ChiangAY. Single- and multiple-dose randomized studies of blosozumab, a monoclonal antibody against sclerostin, in healthy postmenopausal women. J Bone Miner Res. 2014;29(4):935–43. doi: 10.1002/jbmr.2092
478.
PadhiD, JangG, StouchB, FangL, PosvarE. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res. 2011;26(1):19–26. doi: 10.1002/jbmr.173
479.
PadhiD, AllisonM, KivitzAJ, GutierrezMJ, StouchB, WangC, et al. Multiple doses of sclerostin antibody romosozumab in healthy men and postmenopausal women with low bone mass: A randomized, double-blind, placebo-controlled study. J Clin Pharmacol. 2014;54(2):168–78. doi: 10.1002/jcph.239
480.
ReckerRR, BensonCT, MatsumotoT, BologneseMA, RobinsDA, AlamJ, et al. A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density. J Bone Miner Res. 2015;30(2):216–24. doi: 10.1002/jbmr.2351
481.
LiX, OminskyMS, NiuQT, SunN, DaughertyB, D’AgostinD, et al. Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res. 2008;23(6):860–9. doi: 10.1359/jbmr.080216
482.
YaoW, ChengZ, ShahnazariM, DaiW, JohnsonML, LaneNE. Overexpression of secreted frizzled-related protein 1 inhibits bone formation and attenuates parathyroid hormone bone anabolic effects. J Bone Miner Res. 2010;25(2):190–9. doi: 10.1359/jbmr.090719
483.
ChoHY, ChoiHJ, SunHJ, YangJY, AnJH, ChoSW, et al. Transgenic mice overexpressing secreted frizzled-related proteins (sFRP)4 under the control of serum amyloid P promoter exhibit low bone mass but did not result in disturbed phosphate homeostasis. Bone. 2010;47(2):263–71. doi: 10.1016/j.bone.2010.05.010
484.
NakanishiR, AkiyamaH, KimuraH, OtsukiB, ShimizuM, TsuboyamaT, et al. Osteoblast-targeted expression of Sfrp4 in mice results in low bone mass. J Bone Miner Res. 2008;23(2):271–7. doi: 10.1359/jbmr.071007
485.
WangFS, LinCL, ChenYJ, WangCJ, YangKD, HuangYT, et al. Secreted frizzled-related protein 1 modulates glucocorticoid attenuation of osteogenic activities and bone mass. Endocrinology. 2005;146(5):2415–23. doi: 10.1210/en.2004-1050
486.
AlbersJ, SchulzeJ, BeilFT, GebauerM, BaranowskyA, KellerJ, et al. Control of bone formation by the serpentine receptor Frizzled-9. J Cell Biol. 2011;192(6):1057–72. doi: 10.1083/jcb.201008012
487.
MinearS, LeuchtP, JiangJ, LiuB, ZengA, FuererC, et al. Wnt proteins promote bone regeneration. Sci Transl Med. 2010;2(29):29ra30. doi: 10.1126/scitranslmed.3000231
488.
BennettCN, OuyangH, MaYL, ZengQ, GerinI, SousaKM, et al. Wnt10b increases postnatal bone formation by enhancing osteoblast differentiation. J Bone Miner Res. 2007;22(12):1924–32. doi: 10.1359/jbmr.070810
